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ABSTRACT 
 
Recent statistics reveal breast cancer as the most common cancer among women 
and accounts for approximately 41,000 mortalities per year.  In diagnosis, features such 
as stage, grade, lymph node metastasis are important prognostic indicators that help guide 
physicians and oncologist towards optimal patient care.  Presence of established 
pathological markers such as ER, PR, and Her2/neu status would indicate ideal adjuvant 
therapy situation.  Although treatment of these types of breast cancer is well established, 
cancer that lack all three receptors, “triple negatives” or “basal like” do not respond to 
adjuvant therapy and are considered more aggressive in that patients tend to recur early 
and experience visceral metastasis.  Although scientists have uncovered numerous 
molecular biology mechanisms in search of an understanding in cancer, leading to 
development of fields such as apoptosis or growth pathways; cell cycle; angiogenesis; 
metastasis; and more recently cancer stem cells, much work remains as cancer is still not 
eradicated. 
 
MicroRNAs (miRNAs) are post transcriptional regulators of gene expression.  
Their discovery and functional understanding have only been uncovered in the past ten 
years.  Long pri-miRNAs are transcribed from the genome and processed into pre-
miRNAs by Dicer; and then into short single stranded mature miRNAs complexed with 
Argonaute proteins to inhibit protein translation.  The first link of miRNAs to cancer was 
made only relatively recently, but the field has expanded exponentially since. 
 viii
 
TGF-β induced Epithelial to Mesenchymal Transition model in Normal Mouse 
Mammary Gland Epithelia Cells (NMuMG) is a commonly used model to dissect the 
molecular processes of breast cancer metastasis.  Using miRNA microarray, we 
demonstrated miR-155 was upregulated along with alterations of other miRNAs.  This 
observation was validated with Northern and qRT-PCR analysis.  Promoter and ChIP 
analysis revealed TGF-β activated the Smad4 transcriptional complex to induce the 
expression of miR-155.  The reduction of RhoA protein levels by ubiquitination has been 
described to be a critical step during EMT, and we showed miR-155 down regulates 
RhoA proteins without degrading its mRNA levels; therefore, preventing de novo 
synthesis of RhoA proteins in the course of EMT.  The interaction between miR-155 and 
RhoA’s 3’UTR was confirmed by reporter assays.  In summary, we reported the 
importance of miR-155 during TGFβ induced EMT in NMuMG cells. 
 
FOXO3a is a well studied tumor suppressor transcriptional factor and resides in 
the nucleus to transcribe pro-apoptotic genes such as Bim, or p27 in the active state.  
During conditions when cells are signaled to grow and divide, it is phosphorylated by 
oncogenes such as AKT or IKKβ, becomes inactivated and translocates into the 
cytoplasm.  We have shown for the first time that FOXO3a activity is also regulated by 
miRNAs, specifically miR-155.  Western and Northern analysis revealed a correlation 
between FOXO3a protein and mature miR-155 RNA levels in breast cancer cell lines 
along with breast tumor and normal tissues.  Specifically, miR-155 expression is low in 
BT474 and high in HS578T, and inversely correlates with endogenous FOXO3a protein 
 ix
levels.  Overexpression of miR-155 decreased endogenous FOXO3a protein and 
knockdown of miR-155 HS578T rescued its expression.  Reporter assay experiments 
validated the interaction between miR-155 and FOXO3a 3’UTR.  More importantly, 
overexpression of miR-155 in BT474 protected the cells from apoptosis induced by drugs 
while knockdown of miR-155 in HS578T initiated cell death even in the absence of drugs.  
In summary, we have shown the importance of miR-155 in chemosensitivity by targeting 
FOXO3a in breast cancer. 
 
MiR-155 has been previously shown up-regulated in multiple types of 
malignancies, including breast cancer.  In addition, miR-155 expression was reported to 
correlate very strongly to survival in lung and pancreatic cancer.  We validated by qRT-
PCR and Northern analysis that miR-155 expression is detected only in breast tumors and 
not normal breast tissue.  In situ hybridization of breast cancer tissue microarrays 
revealed similar results.  In light of previous studies that showed a correlation between 
miR-155 and survival in lung and pancreatic cancers, we performed an X-tile analysis to 
determine an optimal cut point for miR-155 level in our breast cancer sample population 
that would correlate to ten years overall survival.  Verification using Kaplan-Meier 
validated a cut point at 90.14 to significantly correlate to overall survival (P=0.007).  In 
addition, Chi-square analysis revealed miR-155 expression to correlate with high tumor 
stage, grade and lymph node metastasis.  However, miR-155 expression did not 
correspond to ER, PR, or HER2/neu status, but this is hardly surprising since 
computational analysis does not predict miR-155 to target these genes.  In summary, we 
have shown deviant expression of miR-155 in breast cancer.  Due to its correlation with 
 x
overall survival; higher grade and stage; lymph node metastasis, and triple negative 
subtype, miR-155 may prove to be a valuable prognostic marker and therapeutic target 
for breast cancer intervention. 
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CHAPTER I 
 
INTRODUCTION TO MICRORNA AND BREAST CANCER 
 
Breast Cancer: 
 
According to Breast Cancer Facts and Figures 2009-2010 (The American Cancer 
Society), breast cancer is the most common cancer among women in the United States.  
In 2009, over 190,000 women were diagnosed with breast cancer, and close to 41,000 
died from this disease.  Although much progress has been made since American Joint 
Committee on Cancer (AJCC) and International Union for Cancer Control (UICC) 
established initiatives of standardizing cancer screening, diagnosis, and prognosis leading 
to proper management and choice of therapeutic methods, much work remains in the 
eradication of breast and all other types of cancer. 
In diagnosis, standard clinical features such as the tumor size, extent of lymph 
node involvement, and distant metastasis at diagnosis have all been integrated into the 
AJCC TNM classification standard and still play a central role in determining prognosis 
and treatment course by the physician (49, 73, 100, 104).  Similarly, Estrogen Receptor 
(ER) and Progesterone Receptor (PR) status have been defined as important markers of 
breast cancer pathology decades ago, but now are gold standard in prescribing adjuvant 
therapy today (6, 25, 47, 59, 85-87, 125, 132, 141).  Another feature of breast cancer 
tested for is amplification of Human Epidermal growth factor Receptor 2 (Her2/neu).  It 
is a cell membrane surface-bound receptor tyrosine kinase belonging to the epidermal 
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growth factor receptor family (ErbB) involved in signal transduction pathways promoting 
cell growth and differentiation (24, 103, 111, 112).  Although its presence indicates 
aggressive tumor, trastuzumab, a specific antibody that targets the cell surface receptor, is 
supplemented, so that the receptor can be blocked from receiving growth signals (1, 9, 42, 
84). 
A subtype of aggressive breast cancer, called “triple negative” or “basal like”, 
lacks ER/PR/Her2 expression and grows without the need for external growth hormones 
(3, 7, 13, 16, 54).  It is more prevalent in younger women and characterized by early 
recurrence and visceral metastasis to the brain (4, 45, 126).  Fortunately, it is still 
sensitive to conventional chemotherapy and often prescribed concurrently with surgery (4, 
7, 13, 15, 16).  Although the molecular biology of this breast cancer subtype is not yet 
fully understood, it has been associated with BRCA mutations (123, 138). 
Extensive research that spanned decades has resulted in the gold standard 
diagnostic algorithm that physicians and oncologists depend on to determine treatment 
strategy for the patient diagnosed with breast cancer.  As research continues, this 
algorithm can develop into a more sophisticated system better suited to the dynamic and 
unique characteristics of each individual patient.  One example where change has 
occurred is breast cancer nodal involvement.  Classification were initially based on 
mainly location and extent of macro spread but has been modified to number of nodes 
involved instead.  Modern classification now groups patients into 1-3, 4-9 and finally 10 
or more positive nodes and provides strong correlation to overall survival (8, 65, 118, 
133).  To reiterate the growing need for individualized therapy, roughly a quarter of node 
negative breast cancer patients will experience atypical recurrence correlating to poor 
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overall survival without much molecular understanding.  However, work has shown that 
other features such as late stage and high grade can override the positive effects of 
negative node involvement feature (38, 102).  Although tremendous progress has been 
made in breast cancer diagnosis and treatment, more work remains to be done to provide 
better patient care.   
At molecular levels, significant progress has been made through the identification 
of a number of molecules involved in breast cancer leading to targeted therapy.  
Targeting the oestrogen receptor (ER) is a well-established molecular targeted therapy 
approach, and widespread use of the selective ER modulator tamoxifen in breast cancer is 
responsible for major improvements in cure rates, quality of life and disease prevention 
during the past over 2 decades.  Targeting both HER2/neu with trastuzumab and the 
vascular endothelial growth factor (VEGF) with bevacizumab in combination with 
chemotherapy has become a further milestone in molecular targeted therapy (48, 91, 116).  
However, intrinsic and acquired resistance to endocrine and/or cytostatic treatments is 
still a common feature that limits the benefits of these novel therapeutic strategies. 
Therefore, clinical trials of endocrine or cytotoxic therapies combined with growth factor 
pathway inhibitors or their downstream signalling elements are warranted; such 
approaches may allow us to improve upon the current standard of care for breast cancer 
patients (83).  Unfortunately, despite encouraging preclinical data, some of these 
combinations have yielded disappointing results in the clinical setting (68).  Thus, there is 
an urgent need to identify new molecules which may play critical role in breast cancer 
development, metastasis and chemoresistance.  
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Early Beginnings of RNA Interference and MicroRNAs: 
The discovery of RNA interference (RNAi) began slowly as laboratory 
observations, but developed into a specialized field with widespread implications in basic 
science and clinical medicine.  Two pioneers in this field, Andrew Z. Fire and Craig C. 
Mello, garnered extremely prestigious career achievement recognition by winning the 
Nobel Prize.  History of RNAi traces back to 1971, when a work named “Double-
Stranded Poliovirus RNA Inhibits Initiation of Protein Synthesis by Reticulocyte 
Lysates” (30) provided the first published evidence that short double stranded RNA 
fragments can inhibit protein synthesis.  The next breakthrough occurred in the early 80s, 
when Chalfie et al. described that mutation of the lin-4 gene, now known as a miRNA, 
causes aberrant repetitive regeneration of larval stage specific cuticle in Caenorhabditis 
elegans (20).  This was followed by the description of the elegant orchestration that 
occurs between lin-4, lin-14, lin-28, and lin-29 genes during Caenorhabditis elegans 
development.  Specifically lin-14 and lin-28 were found to suppress lin-29 expression, 
but once development reached the adult stage, lin-4 was generated to suppress lin-14 and 
lin-28, therefore liberating lin-29 to “regulate genes that control cell division, 
differentiation, and stage-specific gene expression” (69).  Furthermore, cloning, mutation, 
and computation analysis of the lin-4 gene did not reveal a coded gene, but instead a 
small RNA transcripts containing 7 consecutive nucleotides in perfect complementation 
to repeat elements found within the 3’ untranslated region (3’UTR) of lin-14.  This 
observation led to the key hypothesis that lin-4 regulates lin-14 expression via antisense 
RNA-RNA interaction in the 3’UTR of messenger RNAs (70, 131).  During this time, 
these molecules were called small temporal RNA (stRNA) as their expression occurred 
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transiently during Caenorhabditis elegans development (67, 69, 70, 131).  Shortly after 
the breakthrough discovery of lin-4, let-7 was also found to also regulate Caenorhabditis 
elegans development by targeting the heterochronic genes lin-14, lin-28, lin-41, and daf-
12 (99).  Similar to Ambros work, let-7 was also found to regulate lin-41 which in turn 
regulates lin-29 (115).  The similarities between the lin-14 and let-7 led researchers to 
consider the possibility that a previously undiscovered level of gene regulation existed. 
This became more evident as scientists almost immediately began identifying other 
stRNAs, and the term microRNA was subsequently coined (66, 67, 69).  Although the 
observation of double stranded RNA fragments blocking protein translation was first 
noted in the early 70’s, it wasn’t until the 90’s that scientists began to unravel the 
mechanism of RNA interference.  Around the same time, the discovery of miRNAs lin-
14 and let-7 probably provided a symbiotic feed forward growth towards better 
understanding of RNA interference.  Since then the field has branched into sub categories 
such as utilization of RNAi as a simple tool to knockdown gene expression in order to 
determine function.  In other areas, disease signatures revealed by microRNA expression 
profiling studies have expanded the field of oncogenes or tumor suppressors and opened 
up new possibilities in medicine using RNAi to lower unwanted gene expression and vice 
versa. 
 
MicroRNA Profiling: 
Since the discovery of RNA interference and miRNAs, accumulated studies have 
shown that miRNAs control cell proliferation, differentiation, and apoptosis (22, 88, 134, 
136).  These broad functions suggest that miRNAs may also contribute to a range of 
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diseases.  In fact, miRNA expression profile studies have demonstrated aberrant 
expression of miRNA in human cancer, heart disease, diabetes, and neurological 
disorders (5, 34, 37, 52, 53, 63, 80, 105, 109, 122).  Beyond pathological association, labs 
have branched into areas of specialty including: (1) new miRNA discovery by sequence 
analysis and cloning; (2) functionality by target identification, classification as tumor 
suppressor or oncogene, developmental regulation, signaling pathways and biological 
circuits; (3) biogenesis and maturation by studying transcriptional regulation, Dicer and 
Drosha processing, and RISC integration; (4) clinical utilization by identifying biomarker 
signature or therapeutic agents.  Although the range is wide in these different areas of 
specialty, many of them will have one technique in common, initial profiling studies to 
determine a signature. 
 
1) Evolution Of Mirna High Throughput Analysis:  
MiRNA high throughput analysis has grown to become a field of its own. Array 
technology that was created for cDNA expression profiling was applied to expression 
profiling of miRNAs (76). Krichevsky and others were one of the first in this field to 
describe a dot blot method that can be easily replicated with standard lab equipments and 
reagents (63). Croce’s lab described an optimized method, which detects both mature 
miRNAs and their precursor forms (75). Due to sensitivity issues, the size of oligo arrays 
have been scaled down considerably from hand held spotting devices to robotics that can 
print microscopic oligo dots onto a glass platform and later by direct synthesis through a 
photochemical process onto a quartz platform (76). However, retrotranscription and 
subsequent amplification through polymerase chain reaction (PCR) addressed the 
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sensitivity issue and took it to the next level by being able to profile using only 
nanograms of total RNA (21, 107, 108, 113). Since then, new techniques have been 
developed by innovating new approaches that ultimately stem from these foundational 
methods. In general, all existing methods can be separated into two categories—one that 
utilizes direct oligo hybridization without sample RNA amplification and the other 
requiring sample amplification (Figure 1). A caveat to keep in mind is that there are 
inherent advantages and disadvantages to both approaches. Protocols that do not utilize 
sample amplification will require a relatively larger starting amount of total RNA. 
However, protocols that require sample amplification could be more prone to external 
variation as handling imperfection can also be amplified. 
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FIGURE 1. Classification of MiRNA Profiling Methods. All high throughput miRNA 
expression analysis methods can be categorized into two groups based on the need 
forRNAsample amplification. The left part is a direct hybridization approach. The right 
part requires RNA sample amplification.  (Kong, W., et al.  2008. Strategies for Profiling 
MicroRNA Expression.  J. Cell. Physiol. 218:22–25, 2009.) 
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2) Array Platform: 
Oligo microarray technology is based simply on the Watson– Crick base pairing 
nature of nucleic acids. Synthesized antisense probes are spotted and immobilized onto a 
nylon support platform using a hand held spotting device (63). This method is relatively 
low cost and readily available to labs without specialized robotics and equipments 
dedicated to array fabrication. A disadvantage to this method is its scale. Oligo spots 
from a hand held device are macroscopic in nature, so the resulting array will be 
relatively large. About 30 mg of total RNA is commonly used to hybridize an array of 
this size (63). To address this issue, automated robots have been employed to spot 
microscopic oligo dots onto a glass slide (75). Another advantage to microscopic oligo 
dots is an increased probe density per given area. Probes designed to differentiate 
between mature miRNA and pre-miRNAs and probes that detect hypothetical miRNAs 
can all be spotted onto the same array. An evolution to this process is the direct 
photochemical synthesis of probes onto a quartz platform (76). 
 
3) Probe Design: 
The design of capture probes has been reported to affect the nature of 
hybridization. Annealing temperature for miRNA is determined by its length and GC 
content, so each miRNA has a signature Tm. An array that contains a library of probes 
can have a Tm that is distributed by a wide range of temperatures. Fortunately, most 
miRNAs are predicted to have a Tm of 55OC (62, 129), and this is often designated as the 
Tm of most miRNA microarray. However, sequence truncation or elongation of problem 
probe has been shown as a way to normalize their Tm to 55OC. For example, probe can 
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be truncated to lower their Tm, and flanking premiRNA sequences can be added to raise 
Tm (10, 40). Another approach is chemical modification of capture probes. Locked 
nucleic acid (LNA) and 2’-O-(2-methoxyethyl)-(MOE) are such examples. Since 
chemically modified probes can elevate Tm and stabilize hybridization, this approach 
allows an entire library of probes designed to have a normalized Tm of 55OC (12, 17, 18). 
Unfortunately, synthesis and chemical modification of RNA probes can be costly.  To 
address this issue, simple concatamerization of DNA probes have been found to be a cost 
effective alternative (62). 
 
4) MiRNA Q-RT-PCR: 
Profiling Direct hybridization of miRNA samples onto an oligo array may require 
a large amount of total RNA; however, some research protocols might have access to a 
small and limited amount of RNA—such as needle biopsies. A PCR based approach was 
developed to address this issue. In this method, total RNA is isolated as usual. However, 
a reverse transcriptase (RT) reaction follows. The RT reaction first consists of small RNA 
fractionation, followed by polyadenylation. Then a standard RT protocol is applied where 
poly(T)s are added to prime the synthesized the poly(A) tail so reverse transcriptase can 
produce cDNAs from the small RNA. Finally, miRNA specific primers will probe for a 
specific miRNA through PCR amplification (107, 113). Due to specificity issues and 
inability to differentiate between mature and pre-miRNA, changes have been made to the 
RT step. Instead of a general poly(A) reaction in combination with universal priming 
through poly(T) adapter molecules, a miRNA specific stem-loop reverse primer is used. 
This specially designed primer contains sequence that is antisense to a portion of the 30 
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sequence of the miRNA that is to be amplified. To increase the specificity of the PCR 
amplification step, the forward primer contains antisense sequence derived from the 
mature miRNA, and the reverse primer consists of sequences taken from the stem-loop of 
the reverse primer. Sensitivity and specificity was found to be dramatically improved. In 
addition, the nature of specific priming allows this protocol to differentiate between the 
longer pre-miRNA and shorter mature active form of the miRNA. Finally, it is claimed 
that this protocol can discriminate between isoforms of related miRNAs that differs by 
only one or two base pairs (21, 108). A multiplexed kit that applies this technology into a 
high-throughput format is now commercially available. 
 
5) Bead Based Method: 
Bead based profiling method involves both amplification and hybridization, and 
requires flow cytometry for analysis. Capture probes for a specific miRNA are 
synthesized and attached to a bead that is uniquely coded by a mixture of two fluorescent 
dyes for identification. Total RNA are enriched for short RNAs. As indicated in Figure 2, 
adapter oligos are then ligated to both the 30 and 50 ends of enriched RNAs. Primers 
with sequence specific to adapters are used to create a library of cDNAs through reverse 
transcription. Finally, a PCR reaction using primers antisense to the adaptors is 
performed to amplify the population of cDNAs. An important feature of this step is the 
use of biotinlyated PCR forward primers to tag each PCR duplex with a biotin molecule, 
which can enzymatically react with streptavidin–phycoerythrin to emit a colored reaction 
that can be registered by a flow cytometer. The resulting PCR product is hybridized to a 
mix of fluorescent beads that make up a miRNA library. This mixture is then run through 
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a flow cytometer to analyze both fluorescent and streptavidin–phycoerythrin intensity. 
The fluorescent bead will indicate the specific miRNA probe, whereas the streptavidin–
phycoerythrin intensity will indicate quantity of a specific miRNA (78). This procedure 
can be relatively labor intensive since it requires both PCR and hybridization steps during 
sample analysis. In addition, a flow cytometer will likely have to be optimized and 
dedicated to scanning this bead based library. 
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FIGURE 2. Diagram Representation of the Bead Based Method for High 
Throughput MiRNA Profiling.  Short RNAs are enriched and then processed with a 
ligation reaction that adds adapter oligos to both 3' and 5' ends of short RNA.  A reverse 
transcription step is carried out using primers that contains sequence to the adaptor oligos 
and followed by PCR using biotinlyated forward primers. The resulting PCR products are 
hybridized to a fluorescent beadmixture containing miRNA specific probes and then 
analyzed with a flow cytometer.  (Kong, W., et al.  2008. Strategies for Profiling 
MicroRNA Expression.  J. Cell. Physiol. 218:22–25, 2009.) 
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6) Mirage: 
The methods described above can only profile known miRNAs. MiRAGE—
miRNA serial analysis of gene expression—uses an amplification based method not only 
profile but also potentially identify new miRNAs. The first half of this protocol resembles 
the bead based method in that linkers are ligated to both 50 and 30 ends of enriched small 
RNAs for reverse transcription. A PCR reaction is carried out on the resulting cDNA mix, 
also with the help of biotinlyated primers. This method deviates from the bead based 
method here. The linkers which now contain biotins are cleaved from the PCR products. 
The mixture containing amplified small RNA sequence and biotinlyated linkers are run 
through a column of streptavidin-coated beads for purification. Streptavidin acts as 
magnets to bind the biotin tagged linkers. The eluted product, at least in theory, is 
purified small RNAs. The small RNAs are concatenated, cloned, and sequenced for 
analysis (27). 
 
7) Rake:  
RAKE, which is short for RNA primed–array-based Klenow enzyme assay, is 
another strategy that involves both hybridization and amplification. However, the PCR 
reaction in this protocol does not amplify the sample, but amplifies the signal. An oligo 
with a 50 spacer is covalently linked onto a glass platform. The spacer sequence is 
followed by a miRNA antisense capture probe with three thymidine residues in between. 
RNA samples are hybridized to this array. MiRNAs in the sample would bind to their 
specific probe and form a double stranded structure. The addition of exonuclease I will 
only degrade unbound single stranded oligos. The miRNA that have latched onto its 
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probe will act as a primer. Subsequent PCR will result in the addition of biotin-
conjugated dATPs onto the spacer template, which emits an augmented signal without 
PCR amplification of the original RNA sample (92). 
 
8) Nanotechnology: 
Though not yet mainstream in the area of biotechnology, nanotechnology is 
finding its way into the miRNA profiling realm. Two methods have been described, and 
both still require the base pairing nature of nucleic acids but do not require sample 
amplification. The first example is a biosensor that has the capability to detect and 
quantitate miRNAs in the femtomolar range. The core of this biosensor consists of a 
microscopic platform made with interlocking gold and titanium microelectrodes with 
wells in between. Capture probes are chemically fixed into these wells. As samples are 
hybridized onto this platform, miRNAs are bound to their probe in specific wells. The 
anionic nature of the miRNA phosphate backbone then catalyzes the formation of 
polyaniline nanowires from a solution of cationic aniline particles, forming a complete 
electrical circuit between the gapped electrodes, and resulting in an immediate digital 
readout (35).  
Another nanotechnology based method utilizes surface plasmon resonance 
imaging (SPRI) in combination with traditional molecular biology enzymatic reactions. 
This multiplexed platform uniquely consists of a single stranded LNA capture probe per 
miRNA. A RNA sample is hybridized to this microarray, followed by poly(A) tailing of 
bound miRNA. Instead of using cy3 or cy5 labeled poly(T)s to base pair with the 
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synthesized poly(A)s, gold nanoparticles attached to poly(T) oligos are used. The 
microarray image is then obtained from a scanner that detects gold nanoparticles (36). 
 
MicroRNA Biogenesis: 
The study of miRNA biogenesis from genomic transcription to the functional 
mature miRNA is an important area of research.  It is now evident that miRNAs appear 
individually or clustered within introns of protein coding genes or ncRNA transcripts; 
while others are found within exons (Figure 3A; 101).  The PolII transcribed primary 
RNA transcript, also known as “pri-miRNA,” is often longer than 1kb and capped at the 
5’ end (56, 57, 74).  A unique feature of this single stranded transcript is the formation of 
stable stem-loop hairpin structures approximately 70 nucleotides in length (Figure 3B). 
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FIGURE 3.  Structures of MiRNA During Biogenesis.  (A)  Schematic structure of 5 
pri-miRNAs.  Red depicts miRNA stems, green non coding, blue introns, beige coding 
exons, (PA) alternate polyA site.  (B)  Typical miRNA stem-loop structure.  (Adapted 
Cullen, B.R.  2004. Transcriptionand Processing of Human microRNA Precursors.  Mol 
Cell 16:861-865.)    
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Drosha and DCGR8, components of the Microprocessor complex, locate and bind 
to the base of each hairpin and cleave approximately 11 nucleotides from the base of the 
stem to free the hairpin from the primary transcript.  This freed particle is called “pre-
miRNA” and consists of an imperfectly complementary double stranded stem at the base 
of the single stranded loop (72, 140).  The structure also contains a 5’ phosphate and a 
distinctive 3’ 2 nucleotide overhang which signals to Exportin-5 for nuclear export (11, 
71, 79, 137).  The transported pre-miRNA then undergoes loop cleavage by Dicer 
resulting in a double stranded RNA with protruding small bulges of non complementary 
nucleotides (44, 50, 58).  Argonaut proteins determine and incorporate the guide strand 
while removing the opposing strand to form the functional mature miRNA complex 
known as RNA induced silencing complex (RISC) (32, 33, 46, 82, 93, 110).  This mature 
miRNA, loaded onto RISC, interact with 3’UTR of targeted mRNAs to induce gene 
silencing by either inhibiting protein translation or mRNA degradation (Figure 4; 28, 51, 
139, 140). 
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FIGURE 4.  Canonical Pathway of MicroRNA Biogenesis.  The production of the 
primary miRNA transcript (pri-miRNA) occurs by RNA polymerase II or III.  Cleavage 
of the pri-miRNA by the Drosha-DGCR8 (Pasha) complex takes place in the nucleus.  
The released precursor stem-loop (pre-miRNA) is exported to the cytoplasm by Exportin-
5-Ran-GTP.  Dicer cuts the loop from the pre-miRNA structure, leaving a double 
stranded RNA with bulges along the stem.  The “diced” RNA double strand is them 
processed by Argonaute proteins into the RNA-induced silencing complex (RISC) where 
it becomes a mature miRNA that inhibits protein translation.  (Adapted from Winter, J., 
et al.  2009.  Many roads to maturity:  microRNA biogenesis pathways and their 
regulation.  Nat Cell Bio  11.3:228-234. 
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MicroRNA Nomenclature: 
As mentioned before, the discovery of miRNAs as post transcriptional regulators 
lead to a rapid discovery of other members by techniques such as sequencing analysis of 
small total RNAs and small RNAs derived cDNA clones; or by computational analysis 
(66, 67, 69, 96).  MicroRNAs are believed to have evolved very early on; and therefore 
are often conserved between species.  Homologus orthologs are named with the same 
numerical identifier, but with a different species prefix, i.e. hsa-miR-155 in human vs 
mmu-miR-155 in mouse.  Paralogs that differ in one or two nucleotides in the mature 
sequence are given a lettered suffix after the numerical identifier, such as members of let-
7 family.  Distinct hairpin structures from different loci in the genome giving rise to the 
same mature miRNA are given a numbered suffix, i.e. miR-199a-1 and miR-199a-2.  
Some hairpins will give rise to two equally stable mature miRNAs, and these are given 
the suffix -5p from the 5’ arm or -3p from the 3’ arm, otherwise the unstable strand will 
receive a * notation after the numerical identifier (2). 
 
MicroRNA and Cancer: 
The miRNA paradigm shifted from worm development to cancer when Calin et al. 
identified miR-15 and miR-16 as tumor suppressors at 13q14 in chronic lymphocytic 
leukemia in 2002 (14).  It has been shown that hemizygous or homozygous loss of 13q14 
occurs in more than 50% in B-CLL, mantle cell lymphoma, and prostate cancers, and 
only slightly lower in multiple myeloma; however, detailed genetic analysis of traditional 
genes located in this region yielded inconclusive evidence.  The discovery miRNA 
prompted Calin et al. to revisit information coded within this region.  They discovered 
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the genetic code for two miRNAs, miR-15 and miR-16, are indeed located in this area 
and hypothesized that deletion of 13q14 results in loss of miR-15 and miR-16 
expressions.  This was confirmed when analysis showed 68% of the B-CLL patient RNA 
do not express these two miRNAs (14).  Shortly after, Michael et al. showed a similar 
reduced expression of mature miR-143 and miR-145 in colorectal cancer (90); and 
Metzler et al. showed an accumulation of miR-155 in Burkitt Lymphoma (89), a trend 
repeated in other types of B cell lymphoma including diffuse large B cell lymphoma (31).  
In 2004, Takamizawa et al. showed that let-7 lost in lung cancer, in addition to a direct 
correlation to postoperative survival.  They also found that overexpression of exogenous 
let-7 in lung cancer cell lines leads to growth inhibition (119).  Then Johnson et al. 
published “RAS is regulated by the let-7 microRNA family,” to complement 
Takamizawa’s findings by demonstrating that let-7 is indeed a probable tumor suppressor 
by targeting oncogenic RAS (55).  These landmark studies have established the 
importance of miRNAs in cancer, leading to an exponential growth in miRNA cancer 
research. 
 
MicroRNA-155: 
Accumulated evidence strongly suggests that miR-155 is oncogenic and 
frequently up regulated in various types of human malignancy, including different forms 
of B cell lymphoma and carcinoma of breast, lung, colon, head/neck, and kidney (23, 31, 
53, 60, 77, 128, 130).  Furthermore, several studies associate elevated miR-155 with late 
stage and poor overall survival in several types of cancer (43, 98, 135).  Further, a 
possible link between miR-155 and inflammation in cancer has been reported (117).  
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Moreover, miR-155 transgenic mice develop B-cell lymphoma (26), and miR-155-knock-
out mice exhibit impaired immune function (121).  To date, the majority of validated 
miR-155 functional biology and protein targets define the importance of miR-155 in 
immunology (19, 29, 81, 95, 120, 121) and various forms of lymphoma (31, 60, 94, 97) 
and breast cancer (53, 61, 128). 
Beyond cancer, miR-155 is an essential regulator of cellular physiology, 
particularly important in the mammalian immune system (19, 95, 121).  For instance, 
miR-155 is detected during an immune response in activated mature B and T lymphocyte 
(124), germinal centers B cells (121), and monocytes (117).  BIC/miR-155 knock-out 
mice results in impaired immune response and cytokine production (121), an observation 
that further support the vital role of miR-155 in immunology.  In addition, Down 
syndrome or trisomy 21 is linked with miR-155 up regulation and thus provides possible 
cause of the resulting cognitive impairment and congenital heart defects seen in patients 
(64), indicating much work remains to better understand the role miR-155 play in human 
development and physiology.   
Finally, a number of miR-155 protein targets involved in processes ranging from 
immune response, inflammation, and cell growth/survival have been identified.  The 
transcription factors Pu1 and inositol phosphatase SHIP1 have been validated previously 
as direct targets of the miR-155-mediated immunoresponse (94, 127).  BACH1 and ZIC3 
are targeted by miR-155 and mediate miR-155 function in viral infection (41, 114).  
Moreover, miR-155 represses tumor protein 53-induced nuclear protein 1 (TP53NP1), 
leading to pancreatic tumor development (39). In addition, two studies using gene 
expression microarray analyses have shown that miR-155 and its viral orthologue 
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Kaposi’s sarcoma-associated herpesvirus miRK12– 11 negatively regulate more than 180 
mRNAs, some of which encode proteins involved in cell growth and survival, including 
PCSK5 and Rho GTPase-activating protein 21 (41, 106, 114). 
 
Central Hypothesis: 
MicroRNA plays a critical role in breast cancer metastasis and chemoresistance. 
 
Objectives: 
1)  Determine the role of TGFβ-regulated microRNA, especially miR-155, in EMT and 
breast cancer cell migration, invasion and metastasis. 
2)  Characterize miR-155 regulation of cell survival, growth and chemosensitivity in 
breast cancer. 
 
3)  Ascertain miR-155 as a valuable marker in breast cancer. 
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CHAPTER II 
 
MICRORNA-155 IS REGULATED BY TGFβ/SMAD PATHWAY AND 
CONTRIBUTES TO EPITHELIAL CELL PLASTICITY BY  
TARGETING RHOA 
 
Abstract: 
TGFβ signaling facilitates metastasis in advanced malignancy.  While a number 
of protein-coding genes are known to be involved in this process, the role of miRNAs in 
TGFβ-induced cell migration and invasion is still limited.  By hybridizing a 515 miRNA 
oligo based microarray library, a total of 28 miRNAs were found to be significantly 
deregulated in TGFβ-treated NMuMG but not Smad4-knockdown-NMuMG cells.  
Among upregulated miRNAs, miR-155 is the most significantly elevated miRNA.  
TGFβ induces miR-155 expression and promoter activity through Smad4.  Knockdown 
of miR-155 suppressed TGFβ-induced EMT and tight-junction dissolution as well as cell 
migration and invasion.  Further, ectopic expression of miR-155 reduced RhoA protein 
and disrupted tight junction formation.  Reintroducing RhoA cDNA without 3’UTR 
largely rescued the phenotype induced by miR-155 and TGFβ.  In addition, elevated 
levels of miR-155 were frequently detected in invasive breast cancer.  These data suggest 
that miR-155 could play an important role in TGFβ-induced EMT, cell migration and 
invasion by targeting RhoA and serves as potential therapeutic target for breast cancer 
intervention. 
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Introduction: 
  Metastasis accounts for the majority of death in cancer patients, and thus it is 
crucial to understand the molecular and cellular mechanism that cause primary tumor to 
metastasize.  The most critical step in conversion of primary tumors to metastases is 
attributed to the process known as epithelial-mesenchymal transition (EMT).  EMT is a 
remarkable example of cellular plasticity that involves the dissolution of epithelial tight 
junctions, intonation of adheren junctions, remodeling of the cytoskeleton and loss of 
apical-basal polarity (49, 55).  In cells undergoing EMT, the loss of epithelial cell 
adhesion and cytoskeletal components is coordinated with a gain of mesenchymal 
components and initiation of a migratory phenotype.  
Transforming growth factor β (TGFβ) has emerged as a key regulator of EMT in 
late-stage carcinomas, where it promotes invasion and metastasis (54).  TGFβ binds to a 
heteromeric complex of transmembrane serine-threonine kinases, the type I and II 
TGFβ receptors (TβRI and TβRII).  Following ligand binding to TβRII, the type I 
receptor is recruited to the ligand-receptor complex, where the constitutively active TβRII 
transactivates TβRI.  Activated TβRI phosphorylates the receptor-specific Smad2 and 
Smad3.  Phosphorylated Smad2/3 associates with Smad4 as a heteromeric complex and 
translocates to the nucleus.  This complex binds directly to Smad-binding elements and 
associate with a plethora of transcription factors, co-activators or co-repressors, thus 
leading to transcriptional induction or repression of a diverse array of genes (54).  A 
number of genes that are associated with tumor growth and metastasis have been shown 
to be directly regulated by this pathway, which include induction of COX2, Slug, Snail 
and Twist and repression of Id2 and Id3 (54).  Recent reports have shown the importance 
 38
of microRNA (miR)-200 family down regulation during EMT (2, 12, 21, 36), however, 
functions of up-regulated miRNAs during TGFβ induced EMT remain uncharacterized.   
MiRNAs are a class of 22-nt noncoding RNAs, which are evolutionarily 
conserved and function as negative regulators of gene expression.  Like conventional 
protein-coding mRNA, miRNAs are transcribed by RNA polymerase II and controlled by 
transcription factors (1, 9, 16, 38).  The primary transcript (pri-miRNA) is capped and 
polyadenylated.  The pri-miRNA is processed by the nuclear RNaseIII Drosha and its 
cofactor DGCR8/Pasha to generate a precursor miRNA (pre-miRNA), a 60-70-nucleotide 
RNA that has a stem loop structure (3, 13, 15).  The pre-miRNA is rapidly exported to 
the cytoplasm by exportin-5 in a Ran-GTP-dependent manner, where it is further 
processed by a second RNaseIII, Dicer, to release a mature ~22-nucleotide miRNA.  
Subsequently, the mature miRNA enters a RNA-induced silencing complex (RISC), 
guides RISC to regions of complementarity in the 3’untranslated region (UTR) of target 
mRNAs and triggers either their degradation or inhibition of translation, depending on 
degree of complementarity between miRNA and its target mRNA (24, 44).  Based on 
prediction by publicly available algorithms, each miRNA may have several hundreds to 
potentially thousands of target mRNAs (25, 32).  miRNA profiling has shown 
deregulation of miRNAs in different types of human malignancy, some of which are 
associated with late stage and high grade tumors as well as poor prognosis (29, 34, 35), 
implying that miRNA could play a pivotal role in tumorigenesis and in tumor progression 
to metastasis.    
In the present study, we profiled the miRNA signature of EMT induced by 
TGFβ/Smad pathway in normal mouse mammary gland epithelial cells (NMuMG).  We 
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further demonstrate that miR-155 is a direct transcriptional target of the TGFβ/Smad4 
pathway and mediates TGFβ-induced EMT.  Ectopic expression of miR-155 disrupts 
proper tight junction formation and promotes cell migration and invasion.  Knockdown of 
mir-155 reduces TGFβ-induced EMT, cell migration and invasion.  Moreover, RhoA is 
negatively regulated by miR-155.  Restoration of RhoA using an expression vector 
cloned without the 3’UTR rescued the effects of miR-155-induced phenotypes.  Thus, we 
demonstrated for the first time that miR-155 is regulated by TGFβ/Smad pathway and 
plays a role in mammary epithelial cell plasticity through targeting RhoA.  
 
Materials and Methods: 
1) Cell Line, Treatment and Tumor Specimens:  Mouse mammary epithelial cell line 
NMuMG, cells were purchased from American Type Culture Collection (Manassas, VA).  
Stable Smad4-knockdown (pRetroSuper-Smad4-shRNA) and pRetroSuper (pRS) vector-
transfected (parental) NMuMG cells were kindly provided by Peter ten Dijke (Leiden 
University Medical Center, the Netherlands (5).  The cells were maintained in DMEM 
supplemented with 10% fetal bovine serum (FBS).  Cells were treated with TGFβ at 
concentration 5 ng/ml for time points indicated in the figure legend.  Cell transfection 
experiments were performed with Lipofectamine 2000 (Invitrogen).  Frozen human 
primary breast tumor and normal breast tissues were procured anonymously from patients 
who underwent surgery at H. Lee Moffitt Cancer Center, and each sample contains at 
least 70% tumor cells as confirmed by microscopic examination of sections.  The tissues 
were snap frozen, within 15 min. of accrual to prevent RNA degradation, and stored at –
70°C. 
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2) MicroRNA Microarray, Northern, and qRT-PCR Analysis:  Total RNA from cell lines, 
breast tumor and normal tissue was isolated using Trizol reagent (Invitrogen).  
MicroRNA array profiling was performed as previously described (52).  Briefly, 
oligonucleotide arrays were printed with tri-mer oligonucleotide probes antisense to 515 
miRNAs specific to human and mouse miRNAs on GeneScreen Plus (NEN) membranes.  
The miRNA expression profiling was performed by hybridization of the array with [γ-
32P]ATP labeled small RNA probes prepared from TGFβ-treated and untreated NMuMG 
cells.  To ensure accuracy of the hybridizations, each experimental group was hybridized 
onto three separate membranes.  In addition, eight oligonucleotides with nonmatching any 
known miRNA were used as hybridization controls.  Hybridization signals for each spot 
of the array and background values at 15 empty spots were measured. Raw data were 
further automatically processed in Microsoft Excel. Hybridization signals that failed to 
exceed the average background value by more than three SDs were excluded from 
analysis.  The data were normalized and unsupervised hierarchical clustering analysis 
with average linkage algorithms was performed with GeneCluster.  The results were 
visualized with TreeView.  Differentially expressed miRNAs were identified by using the 
t test procedure within significance analysis of microarray.  
For Northern blot analysis, 20 μg of RNA were separated on 15% denaturing 
polyacrylamide gel and then electroblotted onto a Zeta-Probe GT Blotting Membrane 
(Bio-Rad).  Following transfer, the membrane was dried and UV-cross linked.  The 
probes were prepared using the Starfire Oligonucleotide Labeling System (Integrated 
DNA Technologies) according to the manufacturer’s protocol.  The blots were hybridized 
overnight at 420C in a buffer containing 5 x SSC,  20 mM  Na2HPO4 (pH 7.2), 7% SDS, 1 
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x Denhardt’s, 0.2 mg/ml salmon sperm DNA, and then washed with 1X SSC/1 % SDS 
buffer at 420C (25).  mirVana qRT-PCR was performed according to manufacturer’s 
instruction (Ambion). 
 
3) Immunofluorescence and Immunoblotting.  For immunofluorescence, cells grown to 
60-80% confluence were washed with PBS and fixed with 4% paraformaldehyde.  Cells 
were permeabilized with 0.5% Triton X-100 in PBS prior to the addition of primary and 
secondary antibodies.  Visualization of E-cadherin was performed by staining with 
mouse-anti-E-cadherin (BD Transduction Labs) and then with TRITC conjugated goat 
secondary anti-mouse IgG (Sigma).  Visualization of ZO-1 was performed by staining 
with rabbit-anti-ZO-1 (34) and then with FITC conjugated goat secondary anti-rabbit IgG 
(Sigma).  Fluorescence imaging was taken by confocal microscopy (Leica), and phase 
contrast imaging was taken by an inverted microscope (Nikon).  Immunoblotting analysis 
was carried out as previously described (52). 
 
4) Isolation and Analysis of MiR-155 Promoter.  miR-155 is found within the BIC gene 
on chromosome 21 in human and chromosome 16 in mouse.  The genomic structure of 
human BIC consists of three exons where exon 3 encodes miR-155 (8, 43).  Based on 
transcription start site identified by other groups (33, 53), a 1.0-kb putative promoter was 
amplified by nest PCR using NMuMG genomic DNA as template.  The PCR products 
were cloned to pGL3-basic vector (Promega) utilizing the Hind III-MluI sites and 
resulting construct was confirmed by DNA sequencing.  All-in-one-seq-analyzer software 
was used to identify putative Smad4 binding sites within the miR-155/BIC promoter.   
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5) Chromatin Immunoprecipitation (ChIP) Assay.  NMuMG cells were cultured to 70-
80% confluence and treated with TGFβ at 5ng/ml for 24 hours.  Cells were harvested for 
ChIP analysis as previously described (35).  Briefly, solubilized chromatin was prepared 
from a total of 2 x 107 cells.  The chromatin solution was diluted 10-fold with ChIP 
dilution buffer, and precleared with protein-A beads and preimmune serum.  The 
precleared chromatin solution was divided and utilized in immunoprecipitation assays 
with either an anti-Smad4 antibody or an anti-IgG antibody.  Following wash, the 
antibody-protein-DNA complex was eluted from the beads.  After cross-link, protein and 
RNA were removed and the purified DNA was subjected to PCR with primers specific 
for 2 putative Smad4-binding sites within the BIC/pri-miR-155 promoter.  The 
sequences of the PCR primers used are as follows: 5’-CCAAAGGAATCACTGGAGGA-
3’ and ‘5-CCCACAGGTCACTAGGCAAT-3’.  Amplified PCR products were resolved 
by 1.5% agarose gel electrophoresis and visualized by BioImage.  
 
6) Knockdown of MiR-155.  Knockdown of miR-155 in NMuMG cells were obtained by 
transfection with antisense 2'-O-methyl oligoribonucleotides (ASO) against miR-155 
using Lipofectamine 2000 (Invitrogen).  Transfection complexes were prepared 
according to the manufacturer’s instructions and added directly to the cells at a final 
oligonucleotide concentration of 10 nmol/L.  Following 36 h incubation, cells were 
treated with or without hTGFβ1 (2ng/ml; RD Systems) for different times and evaluated 
for tight junctions and EMT phenotype.  ASO’s were composed entirely of 2’-O methyl 
bases and chemically synthesized by Integrated DNA Technologies (Coralville, IA) with 
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the following sequences: 2’-O-Me-155: 5’-CCCCTATCACAATTAGCATTAA-3’, and 
2’-O-Me-scrambled: 5’AAGGCAAGCUGACCCUGAAGU-3’. 
 
7) Expression Plasmid and Establishment of Stable MiR-155 Expression Cell Lines.  
miR-155 expression plasmid was created according to BLOCK-iT™ Pol II miR RNAi 
Expression Vector Kit’s protocol.  Briefly, the following oligos were cloned into the 
pcDNA™6.2-GW/miR (Invitrogen) vector and designated as pcDNA™6.2-GW/miR-155: 
5’-TGCTGTTAATGCTAATTGTGATAGGGGGTTTTGGCCACTGACTGACCC 
CCTATCAATTAGCATTA-3’and 5’CCTGTAATGCTAATTGATAGGGGGTCAGTC 
AGTGGCCAAAACCCCCTATCACAATTAGCATTAAC-3’.  To generate stable miR-
155 expressing cells, NMuMG cells were transfected with pcDNA™6.2-GW/miR-155 or 
pcDNA™6.2-GW/miR-control vector using Lipofectamine 2000 (Invitrogen).  Following 
selection with blasticidin, stable clonal cell lines were established and examined for 
expression of miR-155 by Northern analysis. 
 
8) RhoA 3’UTR Luciferase Reporter Assay.  To create individual RhoA 3’UTR 
luciferase reporter constructs, 60 bp sequences from putative miR-155 binding sites were 
synthesized and ligated into pMIR-REPORT vector (Ambion) at SpeI and HindIII sites.  
To create full length RhoA 3’UTR reporter, the following primers were used to amplify 
RhoA’s 3’UTR region from mouse cDNA library: 5’ACTAGTGCAGCCTCATGCGGT 
TAAT-3’, and 5’-AAGCTTTTTTTTTAGAAAACTGCCTTTATTCT-3’, digested and 
cloned into pMIR-REPORT vector (Ambion) at SpeI and HindIII sites.  To create mutant 
3’UTR, point mutations were created at first two matching nucleotide within selected 
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putative seeding regions with the following rules: A to T and vice versa; and G to C and 
vice versa.  NMuMG cells were transfected in 24-well plates with 0.10 μg of the pMIR-
REPORT-3’UTR/RhoA luciferase report, 0.05 μg of the normalization plasmid pCMV-β-
galactosidase, and 0.6 ug of miR-155 or control non GFP vector or 5ng/ml of TGFβ.  
Luciferase assays were performed using the Luciferase Assay System (Promega), and 
activities were normalized to β-galactosidase activity (52). 
 
Results: 
1) MiRNA Expression Profiles in TGFβ-Induced EMT in NMuMG, and Smad4 
Knockdown NMuMG Cells:  TGFβ/Smad pathway plays a critical role in promoting 
cancer metastasis.  Previous studies have identified a number of protein-coding genes that 
are regulated by TGFβ/Smad and mediate TGFβ function (54).  Since TGFβ induced 
EMT in NMuMG cells is a frequently used cellular model to study the molecular 
mechanism of cancer metastasis (5, 34), and its miRNA expression signature is not 
completely understood, we proceeded to profile changes using a miRNA microarray in an 
attempt to identify possible miRNAs involved in TGFβ/Smad-induced EMT, cell 
migration and invasion.  Previous studies has shown that stable knockdown of Smad4 in 
different cell lines, including NMuMG, fails to undergo EMT in response to TGFβ 
treatment (5).  As shown in Figure 5A, Smad4 level was decreased by 80% after stable 
transfection of NMuMG with Smad4-shRNA.  As expected, a parental but not Smad4-
knockdown NMuMG cells underwent EMT after TGFβ treatment.  Thus, we treated both 
cell lines with TGFβ for 0, 24 and 36 h to obtain a miRNA signature using three separate 
hybridizations.  Hybridization to a custom microarray, which contains 515 miRNAs, 
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revealed 28 differentially regulated miRNAs in the parental but not in the Smad4-
knockdown NMuMG cells between 0 h and 24 h or 36 h of TGFβ treatment with a P 
value of < 0.05 (Figures 5B and 5C).  Of the 28 listed miRNAs, 9 were up-regulated and 
19 were down-regulated during TGFβ-treatment at both time points (Figure 5C).  Our 
array revealed that the members of the let-7 and miR-30 family miRNAs were 
consistently down-regulated and clustered miRNAs were often regulated simultaneously 
(Figure 5D).  In agreement with previous findings, our array data also show significant 
down-regulation of miR-200c and miR-205 during a mesenchymal phenotype (12).  MiR-
155, miR-214, miR-21 and miR-323 were all found to be significantly upregulated.  We 
selected 5 significantly deregulated miRNAs for validation by Northern blot and qRT-
PCR to determine the accuracy of the array data (Figure 6A and data not shown).   
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FIGURE 5.  MiRNA Expression Profile of TGFβ/Smad-Induced EMT in NMuMG 
Cells.  (A) TGFβ induces cell morphological change of EMT in control (pRS vector-
transfected) but not Smad4-knockdown NMuMG cells. Western blot analysis was 
performed with anti-Smad4 and –actin antibodies in control and Smad4-knockdown 
NMuMG cells (upper panels).  Indicated cells were treated with or without TGFβ for 24 h 
and photographed (bottom panel).  (B) Heatmap representation of miRNAs dysregulated 
during TGFβ treatment in control and Smad4-knockdown NMuMG cells.  (C) The list of 
deregulated miRNAs induced by TGFβ in control but not Smad4-knockdown NMuMG 
cells.   (D)  Chromosomal representation of the deregulated miRNA location within 
mouse genomic DNA.  Clustered miRNAs are simultaneously down-regulated or up-
regulated during TGFβ treatment.        
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We next examined if the promoters of TGFβ-regulated miRNAs may contain 
Smad4 binding element.  Sequence analysis using MATCH and TRANSFAC (22, 29) 
was conducted in a 6-kb DNA region (5 kb upstream and 1 kb downstream from the ends 
of the pri-miRNA), designated as the putative miRNA promoter.  As indicated in Figure 
5C, both mouse and human promoters of TGFβ-deregulated miRNAs contain 1 or more 
Smad4 binding sites, further suggesting that these miRNAs could be regulated by 
TGFβ/Smad pathway and play important roles in TGFβ-induced EMT.   
 
2) MiR-155 is a Direct Target of TGFβ/Smad Pathway:  Since miR-155 is a highly up-
regulated miRNA in TGFβ-treated NMuMG cells (Figures 5C and 6A) and its function 
in metastasis is currently unknown, we investigated if miR-155 is directly regulated by 
the TGFβ/Smad4 pathway.  We cloned a mouse promoter 1.0-kb upstream from the 
transcriptional start site of the BIC (pri-miR-155) gene into the pGL3-basic vector (33, 
53).  Sequence analysis revealed two Smad response elements (CAGAC and 
CTGTCTGT; 23) located at -542bp and -454bp from the transcription start site, which 
are conserved in human miR-155 promoter.  A luciferase reporter assay revealed that 
miR-155 promoter activity is induced by TGFβ in parental but not Smad4-knockdown 
NMuMG cells (Figure 6B).  Deletion mapping showed that the first Smad4 binding site 
(e.g. -454bp) is responsible for TGFβ-induced miR-155 promoter activity (Figure 6C).  
To determine whether Smad4 could directly bind to the Smad-binding site within the 
promoter in vivo, we carried out a ChIP assay.  NMuMG cells were treated with or 
without TGFβ for 24 hours and immunoprecipitated with anti-Smad4 antibody.  Figure 
6D shows that Smad4 specifically bound to the promoter following TGFβ treatment.  
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These findings indicate that miR-155 is a transcriptional target of the TGFβ/Smad 
pathway. 
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FIGURE 6.  TGFβ/Smad Transcriptionally Regulates MiR-155.  (A) Verification of 
TGFβ-regulated miRNAs.   Parental NMuMG cells were treated with TGFβ for indicated 
time points and subjected to Northern blot analysis with indicated probes.  (B) TGFβ 
induces miR-155 promoter activity in parental but not Smad4-knockdown NMuMG cells.  
Diagram shows that a putative mouse miR-155 promoter containing two Smad4-binding 
sites and individual Smad4-binding site deletion mutants were cloned to pGL3 plasmid 
(top panel).   Parental and Smad4-knockdown cells were transfected with pGL3-miR-
155-Luc and treated with or without TGFβ.  Following 36 h incubation, the cells were 
subjected to luciferase reporter assay.  The experiments were done thrice in triplicate for 
each treatment.  (C) The first Smad4 binding site is required for TGFβ-induced miR-155 
promoter activity.  NMuMG cells were transfected with indicated plasmids, treated with 
TGFβ and assayed for luciferase activity.  (D) TGFβ induces Smad4 binding to miR-155 
promoter.  ChIP assay was done in NMuMG cells treated with/without TGFβ.  PCR was 
done with the eluted DNA fragments from anti-Smad4 immunoprecipitates using a set of 
primers that detect the first Smad4-binding site determined important from reporter assay.  
IgG and anti-actin antibody were used as negative controls.    
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3) MiR-155 Facilitates TGFβ-Induced EMT and Tight-Junction Dissolution as Well as 
Cell Migration and Invasion:  We next assessed whether miR-155 plays a role during 
TGFβ-induced EMT.  First, NMuMG cells were transfected with antisense 2'-O-methyl 
oligonucleotides (ASO) against miR-155 and control ASO and then treated with or 
without TGFβ.  Figure 7A shows that miR-155 ASO effectively knocked down miR-155 
induced by TGFβ.  Accordingly, TGFβ-driven morphological changes were reduced by 
knockdown of miR-155 up to 24 hours (Figure 7B).  Immunofluorescent staining against 
E-cadherin and ZO-1 at the same timepoint revealed that tight junction assembly was 
disrupted by TGFβ in control ASO-NMuMG cells but still intact in miR-155-knockdown 
cells (Figure 7C).  In addition, TGFβ-downregulated E-cadherin was rescued by 
knockdown miR-155 (Figure 7D).  To further demonstrate the effect of miR-155 on 
TGFβ function, we established miR-155 stably-transfected cell line by transfection of 
NMuMG cells with pcDNA™6.2-GW/miR-155 following selection with blasticidin 
(Figure 7A).  Ectopic expression of miR-155 alone was not sufficient to induce EMT but 
did cause disruption in cell polarity and tight junction formations (Figures 7E and 7F).    
Moreover, cells overexpressing miR-155 underwent a complete TGFβ-induced EMT by 
12 hours compared to the 24-36 hours it normally takes in the parental control cells in 
response to TGFβ (Figures 7E and 7F).  In addition, E-cadherin level was much lower in 
miR-155 transfected cells than vector-treated cells by 12 hours of TGFβ treatment 
(Figure 7G).   
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FIGURE 7.  miR-155 Mediates the Effect of TGFβ on EMT.  (A)  Ectopic expression 
and knockdown of miR-155.  NMuMG cells were transfected with indicated plasmids 
and oligos.  Following treatment with/without TGFβ, cells were subjected into Northern 
blot analysis with [α−32P]-dATP labeled miR-155 (top) and U6 (bottom) probes.   (B and 
C)  Knockdown of miR-155 inhibited TGFβ-induced EMT and tight junction dissolution.   
NMuMG cells were transfected with miR-155 ASO and control ASO followed by 
treatment with/without TGFβ for 24 hours.  Cell morphology were documented using a 
phase contrast microscope (B) and stained with anti-ZO-1 and -E-cadherin antibodies 
conjugated to FITC and TRITC, respectively.  Arrows indicate the restoration of TGFβ-
disrupted tight junction by knockdown of miR-155 (C).  (D) Knockdown of miR-155 
inhibits TGFβ-downregulated E-cadherin.  NMuMG cells were transfected with control 
and miR-155 ASO, treated with TGFβ treatment for 24 h and then immunoblotted with 
indicated antibodies.  (E and F)  Overexpression of miR-155 disrupted proper tight 
junction formations and accelerated TGFβ-induced EMT.  Stable miR-155-transfected 
and control NMuMG cells were treated with/without TGFβ for 12 h and photographed (E) 
and immunofluorescence-stained with indicated antibodies (F).  Ectopic expression of 
miR-155-promoted tight junction dissolution is indicated with arrows.  (G) Western blot 
analysis of E-cadherin in NMuMG cells that were transfected with miR-155 and then 
treated with TGFβ for 12 h. 
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Furthermore, we assessed the role of miR-155 in cell mobility and invasion.  Cell 
migration was examined using Boyden chambers and "Wound healing" assays.  Cell 
invasion was measured using matrigel coated Boyden chambers as described in Material 
and Methods.  Triplicate experiments showed that stable expression of miR-155 
increased cell migration by nearly double, as illustrated by Boyden chamber and wound 
healing assays (Figures 8A, 8B and 8D).  Further, cell invasion was also significantly 
enhanced by stable overexpression of miR-155 (Figures 8A and 8D).  In contrast, 
knockdown of miR-155 considerably reduced cell migration and invasion (Figures 8C 
and 8D).  Taken collectively, these results indicate that miR-155 plays an important role 
in TGFβ-induced EMT as well as in cell migration and invasion.    
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FIGURE 8.  miR-155 Plays a Significant Role in Cell migration and Invasion.  (A 
and B)  Ectopic expression of miR-155 induces cell migration and invasion.  
pcDNA™6.2-miR-control and pcDNA™6.2-miR-155 stably transfected NMuMG cells 
were examined for cell migration and invasion using Boyden chamber and "Wound 
healing" assays as described in “Materials and Methods”.  (C) Knockdown of miR-155 
reduces cell migration and invasion.  NMuMG cells were transfected with miR-155 ASO 
and control ASO.  Following 36 h of incubation, cells were subjected to chamber cell 
migration and invasion assays using Boyden chambers with or without insertion of 
coating matrigel.  (D)  Statistic analysis.  The experiments in panel A-C were repeated 
thrice.  P values for comparisons are indicated. 
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4) RhoA is Negatively Regulated by MiR-155:  Since miR-155 was significantly 
upregulated after treatment with TGFβ in NMuMG cells (Figures 5C and 6A) and 
mediates TGFβ function in EMT (Figure 7), cell mobility and invasion (Figure 8), we 
proceeded to identify potential targets known to play a role in EMT using RNA22 
microRNA Target Detection and miRBase databases.  Among candidates surveyed, we 
found that the 3’UTR of RhoA, which plays an important role in cell junction formation 
and stabilization (34, 37, 46, 49), contains three highly conserved regions that may serve 
as a binding site for miR-155 as determined by the RNA22 algorithm (Figure 9A). 
To examine whether RhoA is indeed a target of miR-155, NMuMG cells were 
transfected with pcDNA™6.2-GW/miR-155 and pcDNA™6.2-GW/miR-control and 
selected with blasticidin.  Immunoblotting and RT-PCR analyses revealed that RhoA 
protein but not mRNA was considerably decreased in miR-155-transfected cells (Figure 
9B).  As expected, TGFβ treatment reduces expression level of RhoA in NMuMG cells 
(Figure 9C).  However, knockdown of miR-155 largely rescues the inhibitory effects of 
TGFβ on RhoA protein level (Figure 9C).  Since miR-155 downregulates RhoA to drive 
EMT progression, it is reasoned that ectopic expression of RhoA can rescue this 
phenomenon.  Indeed transition towards EMT was hindered when pcDNA3-RhoA that 
lacks a 3’UTR was introduced into a stably miR-155-transfected NMuMG and 
subsequently treated with TGFβ for 24 hours.  As shown in Figure 9D, ectopic 
expression of RhoA decreased tight-junction dissolution induced by miR-155.  These 
results further indicate that RhoA is a target of miR-155 and mediates miR-155’s 
contribution to the control of epithelial cell plasticity.   
 57
Previous studies have shown that TGFβ induces the RhoA protein degradation 
through the ubiquitin-proteasome pathway (34, 49).  Thus, we further examined the 
significance of the protein degradation and miR-155 in regulation of RhoA by TGFβ.  
NMuMG cells were transfected with control or miR-155 antisense 2-O-methyl 
oligonucleotides (ASO) and then treated with or without TGFβ and proteasome inhibitor 
MG132.   Figure 9E shows that neither MG132 nor knockdown of miR-155 alone fully 
rescues TGFβ-downregulated RhoA.  However, the combined treatment of MG132 and 
miR-155/ASO abrogated TGFβ-repressed RhoA expression.  These results indicate that 
both unbiquitination-proteasome pathway and miR-155 mediate TGFβ-regulated RhoA. 
To further demonstrate that RhoA is negatively regulated by miR-155, we 
constructed luciferase reporters that contains each of the three highly conserved seeding 
sites along with their mutants and a construct that contains the full length RhoA 3’UTR.  
To determine if any of the three seeding sites responds to miR-155, the reporter plasmids 
were introduced into NMuMG cells together with pcDNA™6.2-GW/miR-155 or 
pcDNA™6.2-GW/miR vector.  Following 36 hours of incubation, cells were subjected to 
luciferase assay.  Triplicate experiments show that reporter activity for each site is 
reduced by ectopic expression of miR-155 with site one exhibiting a more significant 
response than the two other sites.  When these sites are mutated, the luciferase reporter is 
no longer inhibited by miR-155 (Figures 9F and G).   We then examined if full length 
RhoA 3’UTRis regulated by TGFβ through miR-155.  Triplicate experiments show the 
full length reporter responds to TGFβ, and this response is largely abrogated when 
antisense 2'-O-me oligonucleotides of miR-155 is simultaneously introduced into the 
cells (Figure 9H).  When the same experiments were carried out in the Smad4 
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knockdown NMuMG cell line, the full length reporter does not respond to TGFβ (Figure 
9I).  Furthermore, antisense full length 3’UTR of RhoA fails to respond to miR-155 and 
TGFβ (Figure 9I). 
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FIGURE 9.  RhoA is a Target of MiR-155.  (A) Sequence alignment of miR-155 with 
3'-UTR of RhoA.  The seed sequence of miR-155 matches to three regions of RhoA’s 
3’UTR, which are highly conserved between human, mouse and rat.  (B) miR-155 
reduces RhoA protein but not mRNA expression.  NMuMG cells were transfected with 
pcDNA™6.2-miR-155 and control vector.  After selection with blasticidin, expression 
level of RhoA was determined using Western blot analysis (top panel).  The same blot 
was reprobed with anti-actin antibody (panel 2).  Expression of miR-155 from the same 
set of cells was examined by Northern blot analysis (panel 3).  RT-PCR was performed to 
determine RhoA mRNA levels (panel 5).  U6 and actin were used for loading control 
(panels 4 and 6).  (C) Knockdown of miR-155 rescues TGFβ down-regulation of RhoA.  
NMuMG cells were transfected miR-155 ASO or control ASO.  After 36 h of incubation, 
cells were treated with or without TGFβ for 24 h and immunoblotted with indicated 
antibodies (panels 1 and 2).  A Northern blot was hybridized with indicated probes 
(panels 3 and 4).  (D) Ectopic expression of RhoA-cDNA lacking 3’UTR overrides the 
effects of miR-155 on cell tight-junction dissolution.  MiR-155 stable clonal cells were 
transfected with pcDNA3-RhoA or vector.  Following treatment with or without TGFβ, 
cells were immunostained with anti-ZO-1 antibody.  (E) Inhibition of ubiquitin-
proteasome pathway and miR-155 hinders TGFβ down-regulation of RhoA.  NMuMG 
cells were transfected with control or miR-155 ASO.  Following 48 h incubation, cells 
were treated with or without MG132 and/or TGFβ for 12 h and then subjected to 
immunoblotting (panels 1 and 2) and qRT-PCR (panels 3 and 4) analyses.  (F and G) 
MiR-155 inhibits RhoA 3’UTR luciferase activity.  Cells were transfected with individual 
site of pGL3-Luc- 3’UTR/RhoA (F) and their mutants (G) together with pCMV-β-
galactosidase, pcDNA™6.2-miR-155 or pcDNA™6.2-miR-control vector.  Luciferase 
activities were normalized to β-galactosidase activity.  (H and I) TGFβ and miR-
155 repress full length RhoA 3’UTR but not its antisense in parental NMuMG cells.  
Cells were transfected with indicated plasmids and treated with or without TGFβ for 24 h.  
Luciferase activities were normalized to β-galactosidase activity.  Full length RhoA 
3’UTR responds to TGFβ and miR-155 in parental (H) but not Smad4-knockdown 
NmuMG cells (I).  TGFβ-inhibited reporter activity was abrogated by knockdown of 
miR-155.   MiR-214 was used as a control.  Experiments were done in triplicates for 
standard deviation calculations. 
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5) MiR-155 Expression in Invasive Breast Cancer:  Having observed that miR-155 
mediates TGFβ-induced EMT, cell migration and invasion, we asked if expression of 
miR-155 is associated with cancer invasiveness in human primary breast carcinoma.  A 
total of 62 breast cancer specimens (e.g. 17 non-invasive and 45 invasive breast 
carcinomas) and 5 normal breast tissue were examined for expression of miR-155.  qRT-
PCR (Figure 10A) and miRNA locked nucleic acid in situ hybridization (Figure 10B) 
analyses revealed high levels of miR-155 in 41 of 45 invasive tumors but only in 2 of 17 
non-invasive cancers (Figure 10C).  Expression of miR-155 was very low in normal 
breast tissue (Figures 10A and 10B).  These data further support the findings of miR-
155’s involvement in EMT and invasion as observed in NMuMG cells, and suggest that 
miR-155 could play a pivotal role in breast cancer metastasis. 
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FIGURE 10.  Elevated Levels of MiR-155 are Associated with Invasive Breast 
Cancer.  (A) qRT-PCR analysis of miR-155 expression in human normal, non-invasive 
and invasive breast carcinoma.  U6 was used as control. The numbers represent the band 
density ratio of miR-155 divided by U6.   (B) LNA-ISH.   miR-155 was labeled with 
digoxigenin-ddUTP using the Dig-3’-end labeling kit (Roche) and hybridized to paraffin 
sections of breast cancer.   Representative photomicrographs of sections of a ductal 
carcinoma in situ (DCIS; left) and invasive (right) breast tumor tissues.  (C) Summary of 
qRT-PCR and LNA-ISH analysis. miR-155 was found to be more frequently detected in 
invasive breast carcinoma than non-invasive tumour.  (D)  Schematic illustration of the 
transcriptional induction of miR-155 by TGFβ/Smad pathway and TGFβ down-regulation 
of RhoA through ubiquitination-proteasome and miR-155 cascades.  
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Discussion: 
  Many studies have demonstrated previously that TGFβ pathway plays a critical 
role in breast cancer metastasis (18, 31, 39, 50).  Several TGFβ/Smad-regulated genes 
have been shown to mediate TGFβ signaling in control of cellular processes associated 
with breast cancer metastasis (18, 31, 39, 50).  In this study, we report a miRNA 
expression signature of TGFβ-induced EMT in mouse mammary gland epithelial 
(NMuMG) cells.  Twenty eight miRNAs were found to be significantly deregulated by 
TGFβ in parental but not Smad4-knockdown NMuMG cells.  Further, we showed miR-
155, the most significantly upregulated miRNA, plays an important role in TGFβ-induce 
EMT, cell migration and invasion.  In addition, RhoA was negatively regulated by miR-
155 and reconstitution of RhoA in miR-155 overexpressing cells decreases TGFβ/miR-
155-induced tight-junction dissolution.  Moreover, high expression levels of miR-155 
correlate with invasive breast carcinomas.  These findings are important for several 
reasons.  First, they provide a miRNAs expression signature of TGFβ/Smad pathway in 
mammary gland epithelial cells.  Second, this study established a direct link between 
TGFβ/Smad4 and miR-155 during EMT.  Finally, this is the first study to describe RhoA 
as a direct target of miR-155. 
MiR-155, a product of the BIC gene, is over-expressed in a number of human 
malignancies which include B-cell lymphoma and carcinomas of breast, colon, lung and 
ovary (8, 17, 48, 51, 52).  E(mu)-mmu-miR155 transgenic mice cause B-cell 
malignancies (4) whereas its knockout mice exhibit impaired immune function (40, 45).  
The transcription factor Pu 1 is validated as a direct target of miR-155-mediated 
immunoresponse (47).  Moreover, miR-155 repressed tumor protein 53-induced nuclear 
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protein 1 (TP53NP1) leading to pancreatic tumor development (10).  In addition, NFκB 
and AP-1 transcription factors have been shown to regulate miR-155 expression (20, 33, 
53).  However, functions of miR-155 in cell migration and invasion have not been 
investigated.  Thus, our study provides the first evidence that miR-155 is up-regulated by 
TGFβ/Smad4 pathway and mediates TGFβ-induced EMT and cell invasion. 
Previous computational and experimental studies have focused on the quality of 
sequence match between miRNA and the target (6, 7, 14, 26, 42).  miRNAs negatively 
regulate their target mRNAs through base-pairing interactions, which leads to either 
mRNA degradation or translational inhibition depending on the degree of match between 
the ‘seed sequence’ (positions 2 – 7 at the 5’ side) of miRNA and 3’UTR of mRNA, e.g. 
miRNA targets mRNA degradation, when the seed sequence perfectly matches with 
target 3’ UTR, or inhibits translation, when they are partially identical (6, 7, 14, 26, 42).  
In addition, recent reports indicated mRNA secondary structures may also contribute to 
target recognition due to the fact that there is an energy cost associated with un-
basepairing of the messenger required to make the target site accessible for miRNA 
binding (27, 30).  Kertesz et al. showed that site accessibility is as important as base 
pairing within the seeding region.  Effective miRNA function requires nucleic acids 
flanking the target site, as well as the target itself, to be unpaired in a thermodynamically 
stable fashion (19).  Through the RNA22 algorithm, we found the ‘seed sequence’ of 
miR-155 have potential to bind in multiple regions within the 3’UTR of RhoA.  Of these 
sites, we selected three sites that fit the above mentioned criteria and are highly 
conserved among species.  Further, RhoA 3’UTR reporter assays experiments showed 
miR-155 significantly diminished luciferase activity at all three sites.  To mimic 
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endogenous conditions more closely, we cloned full length RhoA 3’UTR and performed 
experiments using TGFβ instead of ectopic expression of miR-155.  As expected, the full 
length 3’UTR responds to TGFβ, which is inhibited by knockdown of miR-155 in the 
parental NMuMG line but not in the Smad4 knockdown line. 
RhoA is the prototypical member of the Rho GTPase family, which regulates many 
cellular processes, including cellular adhesion, motility, and polarity, and is an important 
modulator of cell junction formation and stability (34, 37, 46, 49).  Previous studies 
showed that TGFβ induces the disruption of tight-junction, cell polarity and EMT 
through ubiquitination and degradation of RhoA by Smurf1 E3 ligase that is activated by 
Par6 (34).  Our study demonstrated that TGFβ downregulates RhoA protein expression 
through up-regulation of miR-155, and thus provided an additional molecular mechanism 
of TGFβ regulation of RhoA (Fig. 10D).  Regulation by miRNAs provide a means for 
cell to prevent protein translation – a mechanism to quickly prevent accumulation of 
proteins by translational inhibition; our findings go hand in hand with earlier findings that 
TGFβ ubiquitinates RhoA for degradation.  In this scenario, induction of miR-155 halts 
the translation of RhoA while ubiquitination degrades translated RhoA proteins.  Based 
on computational program prediction, each miRNA could negatively regulate hundreds 
of protein-coding  mRNAs (6, 7, 14, 26, 42).  Two recent studies, using gene expression 
microarray analysis, showed that miR-155 and its viral orthologue KSHV-miR-K12-11 
negatively regulate more than 180 mRNAs, some of which are involved in cell migration 
and invasion, including GSK3, PCSK5 and Rho GTPase activating protein 21 (11, 41).  
Thus, RhoA is a major but not only target that mediates miR-155 function in control of 
cell polarity, EMT and cell invasion contributing to cancer metastasis. 
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In addition, a previous study reported a miRNA profile in human keratinocytes 
treated with TGFβ.  Four miRNAs were up-regulated and other 4 were down-regulated 
by TGFβ (55).  Of the 8 deregulated miRNAs only 1 miRNA (e.g. miR-21) showed 
consistent change with our results.  This discrepancy could be due to different cell types 
and duration of TGFβ treatment.  Recent reports have indicated the importance of down-
regulation in miR-200 family of miRNAs during TGFβ induced EMT (2, 12, 22, 36).  In 
congruence to previous findings, our array also shows the down-regulation of miR-200c 
and miR-205 during a mesenchymal transition (Figure 6C).  However, the remaining 
members of the miR-200 family were not detected in our array.  This could be due to 
different cell lines used for the miRNA array analysis between our study and previous 
reports (2, 12, 36).  In addition, we showed frequent up-regulation of miR-155 in primary 
invasive breast cancer.  Consistent with this finding, a previously study reported that 
miR-155 is elevated in a metastatic breast cancer cell line MDA-MB-231, but not in a 
non-metastatic line MCF-7 (28).  We also observed that knockdown of miR-155 inhibits 
TGFβ-downregulated E-cadherin whereas ectopic expression of miR-155 enhances the 
TGFβ effects on E-cadherin expression (Figures 7D and 7G).   Sequence analysis shows 
no match between seed sequence of miR-155 and 3’UTRs of E-cadherin, ZEB1 and SIP1 
(12).  Further investigation is required to determine the mechanism of miR-155 down-
regulation of E-cadherin, although it is likely that the effects are indirect but serves as an 
useful EMT indicator.   
In summary, we demonstrated miRNA expression signature of TGFβ/Smad-induced 
EMT in mammary epithelial cells.  All 28 deregulated miRNAs contain at least one 
Smad4 binding site within their putative promoters.  MiR-155 mediated TGFβ/Smad 
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pathway-induced EMT, cell migration and invasion through targeting RhoA.  Further, 
expression of miR-155 is associated with invasive phenotype of breast cancer.  Thus, 
miR-155 could be potential metastatic/prognostic marker and therapeutic target for breast 
cancer metastasis intervention. 
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CHAPTER III 
 
MICRORNA-155 REGULATES CELL SURVIVAL, GROWTH AND 
CHEMOSENSITIVITY BY TARGETING FOXO3A IN BREAST CANCER 
 
Abstract: 
Breast cancer is the second leading cause of cancer death in women.  Despite 
improvements in treatment over the past few decades, there is the urgent need for 
development of targeted therapies.  MicroRNA-155 (miR-155) is frequently upregulated 
in breast cancer.  In this study, we demonstrate the critical role of miR-155 in regulation 
of cell survival and chemosensitivity through downregulation of FOXO3a in breast 
cancer.  Ectopic expression of miR-155 induces cell survival and chemoresistance to 
multiple agents, whereas knockdown of miR-155 renders cells to apoptosis and enhances 
chemosensitivity.  Further, we identified FOXO3a as a direct target of miR-155.  
Sustained overexpression of miR-155 resulted in repression of endogenous FOXO3a 
without changing mRNA levels, and knockdown of miR-155 increases endogenous 
FOXO3a.   Introduction of FOXO3a lacking 3’UTR abrogates miR-155-induced cell 
survival and chemoresistance.  Finally, reverse correlation between miR-155 and 
FOXO3a levels were observed in a panel of breast cancer cell lines and primary tumors.  
In conclusion, our study reveals a molecular link between miR-155 and FOXO3a and 
presents evidence that miR-155 is a critical therapeutic target in breast cancer. 
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Introduction: 
MicroRNAs (miRs) are short single stranded RNAs that have become known as 
important regulators of various cellular processes by controlling gene expression at the 
post-transcriptional level (1-4).  Deregulated miRNAs in cancer function as either tumor 
suppressors (5-7) or oncogenes (8-11) and play a central role in carcinogenesis.  
Accumulated evidence shows that miR-155 is an oncogenic miRNA.  First, miRNA 
profiling studies indicated frequent increase of miR-155 in various types of human 
malignancies including different forms of B cell lymphoma and carcinoma of breast, lung, 
colon, head/neck, and kidney (9, 11-16).  Recent studies have demonstrated association 
of elevated miR155 with late stage and poor overall survival in several types of 
malignancy (17-19).  We have previously shown that miR-155 is induced by TGFβ and 
plays an important role in epithelial-to-mesenchymal transition and demonstrated 
frequent overexpression of miR-155 in invasive breast cancer (20).  Further, a possible 
link between miR-155 and inflammation in cancer has been reported (21).  Moreover, 
miR-155 transgenic mice develop B cell lymphomas (22) and miR-155-knockout mice 
exhibit impaired immune function (23). 
FKHRL1 (FOXO3a) is a major member of the Forkhead transcriptional factor 
family (24).  Members of this family are characterized by a distinctive fork head DNA 
binding domain which is negatively regulated by protein kinases Akt, SGK and 
IKKβ (25−28).  The phosphorylation of FOXO3a by these kinases leads to its 
translocation from the nucleus to the cytoplasm and loss of the pro-apoptotic function.  In 
the unphosphorylated active form, FOXO3a resides in the nucleus and induces cell death 
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by upregulation of apoptotic proteins such as BIM, p27, BNIP3, and 24p3 (29-32) and 
repression of anti-apoptotic molecule FLIP and BCL-XL (33,34). 
To date, the majority of validated miR-155 functional biology and protein targets 
define the importance of miR-155 in immunology (23,35-39) and various forms of 
lymphoma (9,11,40,41);  however, the in depth role miR-155 play in the context of 
human breast cancer is still limited.  Here, we report that miR-155 induces cell survival 
and plays an important role in chemoresistance in breast cancer.  Its anti-apoptotic 
function is mediated by direct translational inhibition of FOXO3a.  Thus, our findings not 
only demonstrate regulation of FOXO3a at post-transcriptional levels but also identify 
miR-155 as a critical therapeutic target in breast cancer. 
 
Materials and Methods: 
1) Cell Lines and Breast Tumor Specimens:  Breast cancer cell lines were obtained from 
ATCC and grown according ATCC recommended culture conditions.  All 
primary/recurrent human breast cancer and normal breast specimens were obtained from 
patients who underwent surgery at H. Lee Moffitt Cancer Center and approved by IRB.  
Each cancer specimen contained at least 80% tumor cells as confirmed by microscopic 
examination.  Tissues were preserved by snap-freeze and stored at -80OC for subsequent 
RNA and Protein extraction. 
 
2) Plasmids:  Lenti-miR-155 and control was purchased from System Biosciences and 
packaged according to protocol.  Hsa-miR-155 and control mimic precursor molecules 
were purchased from Ambion.  miR-155 and control 2-O’-methyl antisense oligos were 
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custom synthesized from IDT-DNA with sequence as previously described (20).  
FOXO3a expression vector was kindly provided by Dr. B. M. T. Burgering. 
 
3) Northern Blot, Locked Nucleic Acid In-Situ Hybridization (LNA-ISH) and 
Immunohistochemical Staining:  Total RNA from cell lines and breast cancer and normal 
tissue was isolated using TRIZOL® reagent (Invitrogen) according to manufacture’s 
protocol.  LNA-ISH and immunohistochemistry were performed as previously described 
(20).  Briefly, LNA probes were synthesized complementary to human mature miR-155 
(5′-CCCCTATCACGATTAGCATTAA-3′) and scrambled negative control (5′-
TTCACAATGCGTTATCGGATGT-3′) and digoxigenin-labeled at the 5′ end (Exiqon).  
Northern analysis on breast cancer cell lines and tissue RNA were performed using 
StarfireTM oligo labeling kit (IDT-DNA). 
 
4) MiRNA RT-qPCR Detection and Quantification:  Hsa-miR-155 and U6 microRNA 
levels were detected using TaqMan® microRNA Reverse Transcription kit (Applied 
Biosystem).  Briefly, 200ng of total RNA from each cell lines and tumor RNA were used 
for primer specific reverse transcriptase for both hsa-miR-155 and U6, and then 2ul of the 
RT product was used for subsequent qPCR.  The qPCR was performed on ABI HT9600 
and data was collected and analyzed using ABI SDS version 2.3.  To calculate relative 
concentration, miR-155 and U6 CT values for all samples were obtained.  A normalized 
expression for each sample was obtained by dividing CT of miR-155 by the same 
sample’s U6 CT and designated as ΔCT.  This value is then transformed by performing 2^-
(ΔCT).  Furthermore, the (ΔΔCT) method was used in comparing miR-155 expression in 
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immortalized cells to cancer cell lines or normal tissue to cancer tissue according to 
ABI’s protocol. 
 
5) Cell Viability and Apoptosis Assays:  Optimal drug concentration for induction of 
apoptosis in BT-474 and Hs578T cell lines were titrated by measuring cleaved caspase 
activity with Caspase-Glo® 3/7 assay (Promega).  Titration results determined the 
following concentrations for all subsequent experiments:  doxorubicin 5uM, paclitaxel 
5nM, and VP-16 400uM.  After transfection of miR-155 mimic (BT-474) or 2’-O-me 
anti-miR-155 (Hs578T) and treatment with individual drug, cell viability was examined 
with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as 
previously described (42).  Apoptotic detection assay were performed using Cell Death 
Detection ELISAPLUS kit according manufacture’s protocol (Roche), and Caspase-Glo® 
3/7 Assay (Promega).  Each experiment was repeated at least three times in triplicate.  
The results are expressed as the enrichment factor relative to the untreated controls. 
 
6) Western Blot Analysis and Antibodies:  Western analysis was performed as previously 
described (20).  The following antibodies were used:  rabbit-anti-FOXO3a (Abcam), 
rabbit-anti-cleaved PARP (Cell Signaling), rabbit-anti-total PARP (Cell Signaling), 
mouse-anti-β-actin (Santa-Cruz), rabbit-anti-p27 (Cell Signaling), and rabbit-anti-Bim 
(Cell Signaling). 
 
7) Target In-Vitro Luciferase Report Assay:  The pMIR-Report plasmids for the miR-155 
target FOXO3a 3’UTR were constructed as wild type (WT) pmiR-FOXO3a containing 
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two tandem repeats of miR-155 response element from FOXO3a 3’UTR and as mutant 
(MUT) pmiR-FOXO3a by replacing 2 nucleotides within the “seed sequence” (Figure 
2A).  The sequences used to create the pmiR-FOXO3a are as follow: forward,  
5'-ctagATGAACTTACAGGTGAGCATTAAATGAACTTACAGGTGAGCATTAA-3'  
and reverse,  
5’-agctTTAATGCTCACCTGTAAGTTCATTTAATGCTCACCTGTAAGTTCAT-3’.   
The oligos were annealed and inserted into the pMIR-Report vector (Ambion).  The 
empty vector (pMIR-REPORT) was used as a negative control.  Cells were transfected 
with 0.2μg of the reporter plasmids, 0.1μg of pCMV-β-gal, and where applicable 5nM of 
miR-155 precursor or control, or 50nM of miR-155 ASO or control per well on 96-well 
plates.  Following 24 h incubation, cells were subjected to luciferase reporter assay using 
the Luciferase Assay System (Promega). Luciferase activities were normalized by β-gal 
activities.  Each experiment was repeated at least three times in triplicate. 
 
8) Statistic Analysis:  Statistic significance was analyzed by unpaired Student’s t test, and 
P≤0.05 was considered to be statistically significant. 
 
Results: 
1) MiR-155 Is a Determinant in Chemosensitivity of Breast Cancer:  In light of several 
studies, including ours, showing frequent upregulation of miR-155 in breast cancer (13, 
15, 20), we examined the role of miR-155 in breast cancer cell growth, survival and 
response to chemotherapeutic agents.  Initially, we evaluated miR-155 expression in 12 
breast cancer cell lines by quantitative RT-PCR.  Three cell lines, MDA-MB-157, MDA-
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MB-435, and HS578T, had significantly elevated levels of miR-155 whereas the 
remaining cell lines had lower expression of miR-155 (Figure 11A and Table 1).  To 
examine the effect of miR-155 on chemosensitivity, we ectopically expressed miR-155 in 
BT-474 (e.g., low miR-155) and knocked down miR-155 in HS578T (e.g., high miR-155) 
cells.  The cells infected with lentiviral vector and transfected with scrambled RNA 
oligonucleotides were used as controls (Figures 11B and 11C).  Notably, modulation of 
miR-155 alone is sufficient to significantly affect cell growth and the programmed cell 
death, i.e., ectopic expression of miR-155 in BT-474 promotes cell proliferation and cell 
survival (Figures 11 D-F; P<0.05) whereas depletion of miR-155 in HS578T induces 
cell growth arrest and apoptosis (Figures 11G-I; P<0.01).  Moreover, expression of miR-
155 renders BT-474 cells resistance to doxorubicin, VP16 and paclitaxel (Figures 11E 
and 11F).  On the other hand, knockdown of miR-155 sensitizes HS578T cells to 
apoptosis induced by doxorubicin, VP16 and/or paclitaxel (Figures 11H and 11I).  These 
data indicate that miR-155 is a determinant of chemosensitivity in breast cancer cells. 
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FIGURE 11.  MiR-155 Induces Breast Cancer Cell Growth and Survival and 
Chemoresistance.  (A)  miR-155 and U6 expression in 12 breast cancer cell lines was 
determined by real-time PCR.  Relative expression was calculated by obtaining ΔCT, 
where the CT value of miR-155 was divided by the U6 CT from the same sample, the 
resulting value was then transformed by applying 2^-(ΔCT).  (B and C)  Northern blot.  
BT-474, expressing low endogenous miR-155, was stably infected with lentivirus 
expressing miR-155 and vector (B).  HS578T cells, presenting high endogenous miR-155, 
were transfected with anti-miR-155 (ASO) and control oligo (C).  After incubation of 24 
h, total RNAs were isolated and subjected to Northern blot analysis with indicated probes.  
(D - F) Expression of miR-155 induces cell growth, survival and chemoresistance.  miR-
155- and vector-infected or oligo mimics transfected BT-474 cells were treated with and 
without doxorubicin for indicated times (D) or indicated chemotherapeutic agents for 24 
h (E and F).  The growth curve was determined by counting cell number at different time 
points (D).  Apoptosis was assayed with Cell Death Detection ELISAPLUS kit (E) and 
caspase 3/7 activity (F).  (G - I)  Knockdown of miR-155 inhibits cell growth/survival 
and sensitizes cells to chemotherapeutic drug-induced cell growth arrest and apoptosis.  
Anti-miR-155 and scramble oligonucleotide-treated HS578T cells were treated with the 
same agents and assayed with the same methods as described in panels D-F.  Data 
represent three independent experiments with four replicates each.  Asterisks indicate p < 
0.05. 
 83
 
 
 
 
 
       
 
 84
2) FOXO3a is Negatively Regulated by MiR-155:  Since miR-155 plays a significant role 
in cell growth and the programmed cell death, we performed in silico search for miR-155 
targets using MicroRNA.org, TargetScan, MicroCosm, and RNA22.  The 3'UTR of 
FOXO3a, a key transcriptional factor in regulation of cell growth and apoptosis 
(32,43,44), was found to contain a motif (3370 – 3392 bp NM_001455) that matches with 
the “seed” sequence of miR-155  (Figure 12A). 
Since BT-474 and MDA-MB-468 cells normally express low levels of miR-155 
and high FOXO3a (Figures 12B and 14A), we transfected the cells with pre-miR-155.  
This resulted in about 50-60% reduction of endogenous total FOXO3a proteins (Figure 
12B and data not shown).  In contrast, HS578T and MDA-MB-157 normally expresses 
low FOXO3a proteins and high miR-155 (Figures 12C and 14A), so we proceeded to 
suppress miR-155 expression with miR-155 ASO.  This resulted in an increase of 
endogenous FOXO3a protein (Figure 12C and data not shown).  However, RT-PCR 
analysis revealed that FOXO3a mRNA levels remained unchanged (Figures 12B and 
12C), indicating miR-155 targets FOXO3a by translational inhibition, not mRNA 
degradation.  
 
3) 3’UTR of FOXO3a Interacts with MiR-155:  To investigate whether miR-155 
repression of FOXO3a is mediated by direct interaction of miR-155 with FOXO3a-
3’UTR, we cloned two tandem repeats of wild type (WT) miR-155-FOXO3a miR-155 
response element (MRE), or mutant (MUT) into pMIR-REPORT plasmid downstream of 
luciferase (Figures 12A and 12D).  Basal levels of pMIR-FOXO3a reporter activity were 
examined in 2 miR-155 low (MDA-MB-468 and BT-474) and 2 miR-155 high (HS578T 
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and MDA-MB-157) cell lines.  As shown in Figure 12E, the reporter activities are 
reversely correlated with miR-155 expression levels, i.e., the activity is high in miR-155 
low cells (e.g., MDA-MB-468 and BT-474) and low in miR-155 high cells (e.g., 
(HS578T and MDA-MB-157).  Further, expression of miR-155 represses pMIR-
FOXO3a-WT but not pMIR-FOXO3a-MUT reporter activity in BT-474 (Figure 12F).  
In contrast, co-transfection of miR-155 ASO and pMIR-FOXO3a-WT in HS578T 
resulted in an increase of luciferase activity, but the same experiment carried out with the 
MUT construct resulted in little change (Figure 12G).  These data indicate that miR-155 
directly targets FOXO3a 3’UTR at MRE (Figures 12A and 12D) to repress FOXO3a 
protein expression. 
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FIGURE 12.  MiR-155 Targets FOXO3a through Interaction with FOXO3a-3’UTR.  
(A)  Sequence alignment of the human miR-155 sequences with a region of the FOXO3a 
3′-UTR (top).  Bottom panel shows mutant of FOXO3a-3’UTR (seed sequence 
mutation) for pMIR-REPORTER, and the mutant nucleotides are bolded.  (B)  
Expression of miR-155 reduces FOXO3a protein but not mRNA levels.  BT-474 cells 
were transfected with pre-miR-155 or control oligo and then subjected to Western (top 2 
panels), RT-PCR (panels 3 and 4) and Northern blot (panels 5 and 6) analyses.  Bottom 
panels are quantification of levels of FOXO3a and miR-155.  (C)  Knockdown of miR-
155 induces FOXO3a protein level.  Hs578T cells were transfected with miR-155 ASO 
and control oligo for 24 hours then examined for FOXO3a and miR-155 levels as 
described in panel B.  Actin was used as loading control for Western and RT-PCR 
analysis.  miR-155 was normalized by U6.  (D)  Tandem repeats of depicted sequences of 
WT and MUT FOXO3a 3’UTR was used for cloning into pMIR-REPORT vector 
downstream of luciferase gene.  Cloning strategy detailed in Experimental Procedure.  (E 
- G) Luciferase reporter assay.  Indicated cells were transfected with indicated plasmids 
and oligo as well as β-galactosidase.  After 24 h incubation, cells subjected to luciferase 
assay.  Luciferase activity was normalized with β-galactosidase.  Relative luciferase 
activities are presented.  Data represent three independent experiments in triplicate.  
Asterisks indicate p < 0.05. 
 88
 
4) Downstream Targets of FOXO3a were Inhibited by MiR-155:  Since FOXO3a is an 
important transcriptional factor that regulates proapoptotic and growth inhibition genes, 
we next examined if expression of Bim and p27, two major downstream targets of 
FOXO3a, is affected by modulation of miR-155 in breast cancer.  Immunoblotting 
analysis with anti-Bim and -p27 antibodies revealed that basal levels of Bim and p27 
were reduced by stable expression of miR-155 in BT-474 cells (lanes 1 and 4 of Figure 
13A) but increased by knockdown of miR-155 in HS578T (lanes 1 and 4 of Figure 13C).  
It has been demonstrated that doxorubicin induces/activates FOXO3a to promote 
apoptosis (45).  Thus, we further determined the effect of miR-155 on doxorubicin-
induced FOXO3a and apoptosis.  Figures 13A and 13B shows that expression of miR-
155 considerably reduced the effects of doxorubicin on FOXO3a, Bim and p27 
expression and PARP cleavage and apoptosis.  In contrast, depletion of miR-155 
enhances doxorubicin-stimulated FOXO3a, Bim and p27 expression as well as PARP 
cleavage and apoptosis (Figures 13C and 13D).   These results further support the finings 
of induction of cell survival and growth by miR-155 through targeting FOXO3a. 
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FIGURE 13.  MiR-155 Inhibits FOXO3a Downstream Targets, Bim and p27, and 
Modulates Doxorubicin Effects on FOXO3a/Bim/p27 and Apoptosis.  Lenti-miR-
155- and vector-stably infected BT-474 cells were treated with doxorubicin at indicated 
time points and then subjected to immunoblotting analysis with indicated antibodies (A) 
and apoptosis assay (B).  (C and D)  Control and anti-miR-155 oligo-treated HS578T 
cells were treated and analyzed as described in panels A and B.  Apoptosis experiments 
were repeated three times in triplicate. 
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5) Introduction of FOXO3a  cDNA Lacking 3'-UTR Largely Abrogates MiR-155 Cellular 
Function:  Since miR-155 directly targets FOXO3a through interaction between FOXO3a 
3’UTR and miR-155, we reasoned that ectopic expression of  FOXO3a by transfection of 
the cDNA that only contains the coding region of FOXO3a should escape the regulation 
by miR-155 and thus attenuate or decrease miR-155 function.  To this end, pcDNA-
FOXO3a lacking 3'-UTR was introduced into miR-155-stably infected BT-474 cells and 
then treated with and without doxorubicin for 24 h.  Immunoblotting analysis revealed 
that the expression of FOXO3a largely attenuated miR-155-inhibitory effect on Bim and 
p27 expression and PARP cleavage (lanes 2 and 3 of Figure 14A).  Further, miR-155-
inhibited apoptosis induced by doxorubicin was also abrogated by ectopic expression of 
FOXO3a (Figure 14B).  Based on these findings, we conclude that the FOXO3a is a 
major target of miR-155 and largely mediates miR-155 anti-apoptotic function. 
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FIGURE 14.  Transfection of FOXO3a cDNA Lacking 3'-UTR Overrides MiR-155 
Effects on Bim and p27 Expression and Cell Survival.  BT-474 cells were transfected 
with indicated constructs and then immunoblotted with indicated antibodies (A).  After 
treatment with and without doxorubicin, cells were assayed for apoptosis (B), and 
caspase 3/7 activity (C).  *, p < 0.05.  Error bars, S.E.   
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6) Inverse Correlation of Expression of MiR-155 and FOXO3a in Breast Cancer:  Having 
demonstrated FOXO3a as a major target of miR-155, we next investigated the correlation 
of between miR-155 and FOXO3a expression in breast cancer cell lines and breast 
tumors.  Of 12 cell lines examined, 3 expressing high levels of miR-155 exhibited 
undetectable or low level of FOXO3a.  Of 9 cell lines with low levels of miR-155, 8 
express high levels of FOXO3a (Figure 15A).   Moreover, we examined 77 human breast 
cancer specimens and 11 normal breast tissues with Western, Northern blots, 
immunohistochemical staining and miRNA-LNA in situ hybridization.  Upregulation of 
miR-155 was detected in 55 breast cancers and 1 normal breast tissues (Figures 15B-D).  
Of the 55 tumors with elevated miR-155, 41 (75%) had low levels of FOXO3a (P<0.001).  
However, 16 of 22 (73%) specimens with downregulated miR-155 present high levels of 
FOXO3a (Figure 15E).  In addition, we examined miR-155 and FOXO3a levels in 38 
recurrent breast cancers due to chemo- or/and radio-resistance.  Immunoblotting and 
qRT-PCR analyses show that 31 recurrent tumors express elevated miR-155 and low 
FOXO3a (P<0.001; Figure 15D and data not shown).  These findings indicate that miR-
155 regulation of FOXO3a in vivo and that elevated miR-155 is associated with  
chemo- or/and radio-resistance in breast cancer. 
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Figure 15.  MiR-155 Inversely Correlates with FOXO3a Expression in Breast 
Cancer Tissue and Cell Lines.  (A)  Western (top 2 panels) and Northern (panels 3 and 
4) analyses of 12 breast cell lines for expression of FOXO3a and miR-155.  Bottom panel 
shows the quantification of FOXO3a and miR-155.  (B and C) Expression of FOXO3a 
and miR-155 was analyzed in representative of breast tumors with Western/Northern blot 
(B), miR-155 LNA-ISH and immunohistochemical staining (C).  (D) Representatives of 
recurrent tumors (RT) were analyzed with qRT-PCR (top; miR-155) and immunoblotting 
analysis (bottom).  (E)  Chi-square test analysis of miR-155 and FOXO3a expression in 
77 breast cancer specimens examined. The inverse correlation is significant (p<0.001). 
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Discussion: 
MiR-155 has emerged as an essential regulator of cellular physiology; particularly 
important in the mammalian immune system (23, 36, 37).  For instance, miR-155 is 
detected during an immune response in activated mature B and T lymphocytes (46), 
germinal centers B cells (23), and monocytes (21).  BIC/miR-155 knock-out mice 
resulted in impaired immune response and cytokine production (23), further supporting 
the vital role of miR-155 in immunology.  Beyond immunology and into the realm of 
development, Down syndrome or Trisomy 21 was recently linked with high levels of 
miR-155 and thus provide further insights to the resulting cognitive impairment and 
congenital heart defects seen in patients (47).  In cancer, deregulation of miR-155 is 
implicated in a wide spectrum of malignancy including various forms of lymphoma, 
breast, lung, pancreatic, head and neck, and kidney cancer (9, 11, 13-15).  In immunology 
and lymphoma, miR-155 has been extensively investigated; however, it is only evident 
that miR-155 expression is elevated in breast cancer (13, 15) and detailed function 
remains elusive.  We demonstrate in this study that miR-155 is a determinant of 
chemosensitivity by targeting FOXO3a in breast cancer.  We show that miR-155 directly 
interacts with 3’UTR of FOXO3a and blocks FOXO3a translation.  As a result, Bim and 
p27, major downstream targets of FOXO3a, are inhibited by miR-155.  Ectopic 
expression of FOXO3a largely abrogated miR-155-induced chemoresistance.  In addition, 
inverse correlation between miR-155 and FOXO3a expression was detected in breast 
cancer cell lines and tumors.  These findings demonstrate for the first time that 
deregulation of miR-155 in breast cancer is associated with chemosensitivity and that 
FOXO3a is a bona fide target of miR-155. 
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FOXO3a is a well studied transcriptional factor that contains a fork head DNA 
binding domain, and plays a crucial role in apoptosis and cell growth by transcriptional 
regulation of a number of apoptosis/cell growth-associated genes (24, 32, 43).  
Overexpression of FOXO3a has been shown to inhibit tumor growth in vitro and tumor 
size in vivo in breast cancer cells (28, 48).  In addition, genetic deletion of all FOXOs 
(FOXO1, FOXO3 and FOXO4) alleles generates progressive cancerous phenotypes, such 
as thymic lymphomas and hemangiomas (49).  These data elucidated FOXOs as bona 
fide tumor suppressor genes.  Recent studies also reveal the importance of FOXOs in 
preserving the self-renewal capacity of hematopoietic stem cells (50,51).  Moreover, 
FOXO3a has been reported to be deregulated in breast cancer and loss of FOXO3a is 
often linked to a decline in apoptotic activity and increased chemoresistance in cancer 
cells (43, 52-58).  In addition, post-translational regulation of FOXOs has been wildly 
studied.  Our finding of miR-155 negative regulation of FOXO3a not only provides an 
underlying mechanism for aberrant expression of FOXO3a in breast cancer but also 
reveals regulation of FOXO at post-transcriptional level. 
In an earlier work, we demonstrated that miR-155 is induced by TGFβ in mouse 
mammary epithelial cell, NMuMG.  Expression of miR-155 promotes whereas 
knockdown of miR-155 reduces TGFβ-induced tight junction dissolution, cell migration 
and invasion by targeting RhoA (20).  Previous studies have shown that miR-155 
regulates a number of genes which are involved in immune response, inflammation and 
cell growth/survival.  The transcription factors Pu1 and inositol phosphatase SHIP1 have 
been validated previously as direct targets of the miR-155-mediated immuno-response 
(40, 59).  BACH1 and ZIC3 are targeted by miR-155 and mediate miR-155 function in 
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viral infection (60,61).  Moreover, miR-155 represses tumor protein 53-induced nuclear 
protein 1 (TP53NP1), leading to pancreatic tumor development (62).  In addition, two 
studies using gene expression microarray analyses showed that miR-155 and its viral 
orthologue Kaposi's sarcoma-associated herpesvirus miR-K12-11 negatively regulate 
more than 180 mRNAs, some of which encode proteins involved in cell growth and 
survival, including CDKN1B/p27kip1, CDKN1C/p57kip2 and GSK3β (60, 61).  Thus, 
FOXO3a is a major but not necessary the only target that mediates miR-155 function in 
the control of cell growth, survival and chemosensitivity. 
Finally, we noticed that miR-155 is more frequently upregulated in breast tumors 
than cancer cell lines.  A possible reason is that miR-155 in tumor cells could be induced 
by cytokines that are released from the tumor microenvironment.  In agreement with this 
notion, miR-155 has been shown to be transcriptionally regulated by NFκB, AP1, and 
Foxp3 in response to cytokines during immune cells maturation and development (36, 
63-65).  We also demonstrated transcriptional regulation of miR-155 via TGFβ/Smad 
pathway (20).  In addition, accumulated studies show that gene expression, biology and 
clinical outcome of cancer are significantly influenced by the microenvironment (66, 67).  
Three-dimensional culture model has been established to recapitulate the in vivo 
functions, interactions and architecture of the mammary gland and breast tumor (66, 67) 
which more closely resembles tumor microenvironment than traditional tissue culture.  In 
order to address if miR-155 expression is influenced by microenvironment, further 
investigation is required using 3-D culture system and animal models. 
In summary, we demonstrated that miR-155 contributes to chemoresistance in 
breast cancer.  FOXO3a is negatively regulated by miR-155 and mediates miR-155 
 99
function in the control of breast cancer cell survival and growth.  In combination with our 
previous findings of miR-155 induction of EMT, cell migration and invasion in 
mammary epithelial cell, miR-155, therefore, is a critical therapeutic target for breast 
cancer intervention. 
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CHAPTER IV 
 
ELEVATED MICRORNA-155 IS ASSOCIATED WITH POOR PROGNOSIS IN 
BREAST CANCER 
 
Abstract: 
 
MicroRNA-155 is often upregulated in various types of malignancy, including 
breast cancer.  However, the clinical and pathological significance of deregulation of 
miR-155 remain elusive in breast cancer.   Here, we evaluated miR-155 expression in 154 
primary breast cancers and 69 normal mammry tissues.  Increase levels of miR-155 were 
oberserved in 67 (43.5%) patients with breast cancer as compared to normal tissue 
controls.  Elevated miR-155 is associated with high grade (49/76, 64.5% versus low grad 
18/78, 23.1%) and late stage (37/70, 52.9% versus early stage 30/84, 35.7%) of tumors as 
well as invasive (53/85, 62.4% versus non-invasive 14/69, 20.3%) breast carcinoma.  
More significantly, miR-155 is frequently overexpressed in lymph node-positive tumor 
(i.e., ≥ 10; 20/32, 62.5%) than node-negative (i.e., < 10; 47/122, 38.2%).  MiR-155 levels 
do not correlate to ER, PR, and Her2/neu expression.  Furthermore, patients whose 
tumors express high levels of miR-155 have shorter overall survival than those of tumors 
with low levels of miR-155.  These findings indicate that miR-155 is unfavorable 
prognostic marker and could be a critical target for triple-negative breast cancer while the 
molecular mechanism needs to be further investigated.    
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Introduction: 
Breast cancer is the most common cancer among women in the United States.  In 
2009, over 192,370 women were diagnosed with breast cancer, and close to 40,170 died 
from this disease.  Clinical features such as the tumor size, extent of lymph node 
involvement, and distant metastasis at diagnosis have all been integrated into the 
American Joint Committee on Cancer (AJCC) TNM classification standard and still play 
a central role in determining prognosis and treatment course (9, 17, 26, 34, 36).  Similarly, 
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptor 2 (Her2/neu) statuses have been defined as important markers of breast cancer 
pathology decades ago, but are still gold standard in prescribing adjuvant therapy today 
(6, 15, 16, 29, 31, 45, 49).  A number of protein-coding genes have been identified to 
play important role in breast cancer development, metastasis and chemoresistance (40); 
however, the importance of microRNAs (miRNAs) in these processes remains to be fully 
documented. 
MiRNAs are a class of small (~22 nucleotide) noncoding RNAs and negatively 
regulate protein-coding gene expression by targeting mRNA degradation or translation 
inhibition (1, 23-25, 38).  MicroRNA-155 (miR-155) is often deregulated in breast 
carcinoma revealed by several miRNA profiling studies (18, 44).  However, its 
clinicopathological significance in human breast cancer is not yet fully understood.  We 
have previously shown that miR-155 regulates cell survival, growth and chemosensitivity 
in breast cancer cells (20).  In this study, we examined miR-155 levels in 154 primary 
breast cancer using quantitative Real-Time PCR (qRT-PCR), Northern, and Locked 
Nucleic Acid-miRNA (LNA-miRNA) in situ hybridization (ISH).  Elevated levels of 
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miR-155 are more frequently detected in high grade, late stage and lymph node-positive 
tumors.  Further, miR-155 expression decreased patient overall survival.  These findings 
suggest that miR-155 could play a pivotal role in breast tumor progression and serves as a 
poor prognostic marker and critical therapeutic target in breast cancer. 
 
Materials and Methods: 
1) Tumor Specimen:  All primary human breast cancer (e.g., 154) and normal breast (e.g., 
59) specimens were obtained from patients who underwent surgery at H. Lee Moffitt 
Cancer Center.  Each cancer specimen contained at least 80% tumor cells as confirmed 
by microscopic examination.  Tissues were preserved by snap-freeze and stored at -80OC 
and formalin fixed paraffin embedded (FFPE) blocks.  The following information on the 
tumors was collected:  histology, primary site and laterality, tumor markers ERα, PR, and 
Her2/neu, clinical and pathological stage and grade, as well as nodal status.  In addition, 
the following information was collected:  age, year first seen, performance status and 
survival days.  All specimens (total 82) were chosen from patients who have at least 120 
months (10 years) of follow up documentation as determined by year first seen at Moffitt. 
 
2) RNA Isolation:  Total RNA from breast cancer and normal tissues was isolated using 
TRIZOL® reagent (Invitrogen) according to protocol and as previously described (20, 21, 
47). 
 
3) QRT-PCR and Northern Blot Analysis:  Hsa-miR-155 and U6 microRNA levels were 
detected using the TaqMan® microRNA reverse transcription kit (Applied Biosystems) as 
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previously described (20).  Briefly, 200 ng of total RNA from each cell line and tumor 
RNA were used for primer-specific reverse transcription (RT) in both Hsa-miR-155 and 
U6, and then 2 μl of the RT product was used for subsequent quantitative PCR.  The 
quantitative PCR was performed on an Applied Biosystems 7900HT® fast real-time PCR 
system, and data were collected and analyzed using ABI SDS® version 2.3.  To calculate 
relative concentration, miR-155 and U6 CT values for all samples were obtained.  A 
normalized expression for each sample was obtained by dividing the CT value of miR-
155 by the same sample's U6 CT and designated as ΔCT.  This value was then transformed 
by performing 2−(ΔCT).  Furthermore, the (ΔΔCT) method was used in comparing miR-155 
expression in immortalized cells with cancer cells or comparing normal breast with 
cancer tissues according to the manufacturer's protocol.  
Northern analysis on breast cancer tissue RNAs were performed as previously 
described.  MiR-155 probe was prepared using the StarfireTM oligonucleotide-labeling kit 
(IDT-DNA).  The expression of miR-155 was determined by comparing the miR155 to 
U6 ratio between normal mammary and tumor tissues (i.e. the ratio miR155/U6 of all 
tested normal mammary tissues were averaged to 1.0, and the cut-off value for 
overexpression of miR-155 is ≥2-fold in breast tumors. 
 
4) Locked Nucleic Acid in Situ Hybridization (LNA-ISH):  LNA probes were 
synthesized complementary to human mature miR-155 (5′-
CCCCTATCACGATTAGCATTAA-3′) and scrambled negative control (5′-
TTCACAATGCGTTATCGGATGT-3′) and digoxigenin-labeled at the 5′-end (Exiqon).  
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LNA-ISH on breast cancer Tissue Microarray (TMA) was performed as previously 
described (20, 21, 48). 
 
5) Statistical Analysis:  Correlations of miR-155 with tumor grade, stage, and histology 
were analyzed by X2 testing.  For survival analysis, optimal cut-point was selected using 
X-tile program as described previously (5, 14).  Monte Carlo simulations were used to 
adjust for multiple looks in optimal cut-point selection.  Hazard ratios were assessed 
using the univariate and multivariate Cox proportional hazards model (Log-rank test at α 
= 0.05) based on the cut-point value determined by the X-tile.  The regression analyses 
were adjusted for AJCC TNM staging (I, II, III, and IV), and histological grade (high and 
low).  Confidence intervals (95% CI) for the corresponding parameters in the multivariate 
Cox regression model were tabulated in Table 5.  Patients’ deaths of non-related breast 
cancer were censored in the survival analyses at the date of death.  These analyses were 
performed using the SPSS 11.5 Statistical Software and P < 0.05 was considered 
statistically significant. 
 
Results: 
1) Frequent Overexpression of MiR-155 in Breast Cancer:  In light of a number miRNA 
profiling studies showing miR-155 up-regulated in breast cancer; we had set out to 
determine if miR-155 could be used as a tumor marker in this malignancy.  RNA was 
extracted from eighty-two snap frozen breast cancer specimen and twenty normal breast 
tissues.  The tumor specimens consisted of ductal, lobular, mixed ductal and lobular, 
mucinous, and comedeocarcinoma.  QRT-PCR for miR-155 and U6 was performed using 
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TaqMan MicroRNA Assay® (Applied Biosystems) as described in Materials and 
Methods (Figure 16A).  Quantitation using the delta delta CT method yielded expression, 
including outlier, ranged from 2.3 to 737.7 in reference to normal breast RNA (Figure 
16B).  To validate specificity and accuracy of qRT-PCR, samples were randomly chosen 
for Northern analysis (Figure 16C).  In agreement to our previous findings (20, 21), 
miR-155 expression was found lower in normal breast RNA compared to cancer RNA 
(Figure 16B). 
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Figure 16.  MiR-155 Expression in Breast Cancer.  (A)  Quantitative real-time PCR 
was performed in 82 human breast cancer tissues and 20 normal human mammary tissues 
to determine relative miR-155 and U6 expression.  (B)  Relative expression levels were 
calculated using the ∆∆CT method, where miR-155 expression in breast cancer was 
compared to that in normal breast tissue and U6 expression was used for normalizing RT-
qPCR samples; * and • outlyers.  (C)  Northern analysis for verification of miR-155 
expression in randomly selected tumor and normal breast tissues.  (D)  In situ 
hybridization for miR-155 on breast cancer tissue microarray: 7 high miR-155 tumors, 65 
low to moderate miR-155 tumors, 49 low to moderate or undetectable miR-155 normal 
tissues. 
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We have previously used formalin fixed paraffin embedded (FFPE) tissue 
microarrays (TMA) to determine microRNA levels by LNA-ISH (20, 21, 47, 48); 
therefore, we performed ISH with LNA-miR-155 probe (Exiqon) in the same series of 
breast tumors used for qRT-PCR and Northern analysis, as well as 72 additional 
carcinoma and 49 normal tissues not available in snap frozen tissue.  We first evaluated 
the specificity of LNA-miR-155 probe by performing ISH in miR-155 precursor-
transfected BT-474 and miR-155-antisense transfected HS578T, cell lines previously 
determined to be low and high in endogenous miR-155, respectively (20).  Signals were 
high in miR-155 transfected BT-474 and parental HS578T, but not detected in control 
oligo transfected BT-474 and miR-155 ASO transfected HS578T (data not shown), 
suggesting the LNA-miR-155 probe specifically hybridized to mature miR-155.  ISH of 
primary breast tumors revealed a range of miR-155 staining intensity in tumor regions 
and were scored by 0, 1, 2, or 3 as determined by negative, weak, moderate, or strong 
respectively (Figure 16D).  The BT-474 miR-155 transfected and endogenous high miR-
155 HS578T cell line ISH staining scored 3, so only tumor cores with a score of 3 were 
considered high for miR-155 expression.  In contrast, normal breast tissue showed low or 
no detectable levels of miR-155. 
QRT-PCR, northern, and/or ISH analyses revealed elevated levels of miR-155 in 
67 of 154 (43.5%) breast cancers examined.  Tumor characteristics from all samples are 
listed in Table 2.  Breakdown of miR-155 expression in these samples are summarized in 
Table 3. 
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Table 2.  Clinical and Pathological Data for Breast Tumors in the Independent 
Validation Cohort 
Breast cancer clinicopathological characteristics  Number of patients (n=154) 
Age 
 < 51        67 
 >51        87 
 
Histologic subtype 
 Ductal carcinoma      135 
 Lobular       10 
 Ductal/lobular mixed      7 
 Others        2 
 Normal tissue       69 
 
Stage 
 Stage 1       35 
 Stage 2       49 
 Stage 3       56 
 Stage 4       14 
 
Grade 
 1        39 
 2        39 
 3        76 
 
Nodal status 
 Node-negative (<10)       122 
 Node-positive (>10)      32 
 
Intrinsic subtype (63 cases with complete data) 
 ER positive       45 
 ER negative       18 
 PR positive       40 
 PR negative       23 
 HER-2/neu positive      11 
 HER-2/neu negative      52 
Clinical and pathological characterization of breast tumor tissue. 
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Table 3.  MiR-155 Expression in Histological Subtype  
Histology N High/Mod Low/No 
Ductal carcinoma in situ 135 53 82 
Lobular carcinoma 10 6 4 
Ductal & lobular carcinoma 7 6 1 
Mucinous adenocarcinoma 1 1 0 
Comedeocarcinoma 1 1 0 
Normal tissue 69 3 66 
Expression of miR-155 in 154 breast cancer specimens and 69 normal mammary tissues. 
 
 
 
 
Table 4.  MiR-155 Expression in Clinical and Pathological Characteristics 
Characteristics N Low/No High/Mod P value 
Age    0.193
     <51 67 42 25  
     >51 87 45 42  
Stage    0.035
     I/II 84 54 30  
     III/IV 70 33 37  
Grade    <0.001
     I/II 78 60 18  
     III 76 27 49  
Node    0.017
     Negative (<10) 122 75 47  
     Positive (>10) 32 12 20  
ER Status (63 cases)    0.279
     ER positive 45 18 27  
     ER negative 18 10 8  
PR Status (63 cases)    0.118
     PR positive 39 14 25  
     PR negative 24 14 10  
Her2/Neu Status (63 cases)    0.257
     Her2/neu positive 11 5 11  
     Her2/neu negative 52 23 24  
Analysis with X2 test. 
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2) MiR-155 Overexpression Is Associated with Clinical Features:  The frequency of miR-
155 overexpression was significantly low in early stage (35.7%) and low grade (23.1%) 
breast cancer when compared to late stage (52.9%) and high grade (64.5%) tumors 
(P=0.035 and P<0.001 respectively; Table 4).  Current understanding in breast cancer 
indicates a higher number (≥ 10) of positive lymph node involvement is often correlated 
with poorer prognosis (3, 22, 42).  We observed that miR-155 expression directly 
associated with lymph node metastasis evaluated at ≥ 10 positive nodes (P=0.017; Table 
4).  Another important aspect of breast cancer is ERα, PR, and Her2/neu receptor status; 
however, miR-155 levels did not correlate significantly with their expression (Table 4). 
 
3) MiR-155 Overexpression Is Associated with Poor Overall 10-year Survival:  We next 
analyzed the association between miR-155 expression with 10-year survival in the 82 
tumors in which 10 years follow-up data are available.  The X-tile algorithm 
automatically determines whether an optimal cut-point exists for the range of miR-155 
expression that results in a statistically significant difference in 10 year overall survival.  
MiR-155 expression of the 82 tumor samples were automatically divided into “training” 
and “validation” for cross-validation analysis (Figures 17A, and B).  The analysis 
determined 90.14 as the optimal cut-point in this data set.  Cross-validation analysis 
revealed that over-expression of miR-155 in validation set had poor overall survival 
(P=0.0077; Figure 17B).  Further, Kaplan-Meier analysis of all 82 samples demonstrated 
a statistically significant inverse correlation between overall survival and miR-155 
expression level (P= 0.008; Figure 17C). 
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To extend this observation, we separated the patients into two groups by stage [eg, 
early stages (I/II) and late stages (III/IV)] and asked whether miR-155 expression could 
predict patient survival within each subgroup.  In both groups, high miR-155 expression 
was still a prognostic factor (Figures 17D, and E), although the result was not 
statistically significant in early stage tumors (P = 0.326; Figure 17D) likely due to the 
small sample size.  In addition, we also evaluated miR-155’s impact on overall survival 
in different grade; we found that patients with elevated miR-155 appear to have poor 
overall survival while P values did not reach significance (data not shown).  These results 
suggest that high miR-155 expression to be an unfavorable prognostic feature that is 
independent of other factors. 
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Figure 17.  MiR-155 Expression Correlates to Ten-Year Overall Survival in Breast 
Cancer.  (A)  MiR-155 low and high expression cut-point that best associates with 
patient 10 year survival within the cancer subpopulation was determined by using the X-
Tile algorithm, where a division at 90.1412 will yield a statistically significant difference 
in 10 year overall survival in original data set, (B) and software randomly derived 
validation set.  (C)  Further statistical analysis on miR-155 expression and correlation to 
10 year overall survival was performed using the Log Rank, Breslow, and Tarone-Ware 
methods on SPSS Statistics version 17.0 and the cut-off at 90.1412 as previously 
determined by X-Tile yields a statistical significance between miR-155 expression and 
patient 10 year survival.  (D)  Overall 10-year survival was also analyzed in patients with 
early stage and (E) late stage breast tumors expressing high versus low levels of miR-155. 
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Further univariate analysis revealed that grade, and miR-155 were associated with 
poor clinical outcome (P<0.05), while stage approached statistical significance (P=0.054; 
Table 5) likely due to sample size.  Of them, miR-155 was a relative strong predictor of 
poor clinical outcome with a hazard ratio of 2.619 (95% CI, 1.322-5.189, P=0.006; Table 
5).  A multivariate Cox proportional hazard analysis with the following variables:  age, 
histology, stage, grade, and miR-155 expression was used to analyze their simultaneous 
association with overall survival.  As expected, the best multivariable model predictive of 
overall survival showed stage as the strongest predictor of outcome with a hazard ratio of 
2.286 (1.330-3.930, P=0.003; Table 5).  In addition, miR-155 expression also appeared 
to be a predictor with a hazard ratio of 2.857 (1.390-5.874, P=0.004; Table 5).  Taken 
collectively, these results suggest that elevated levels of miR-155 are associated with 
poor prognosis in breast cancer. 
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Table 5. Ten-Year Survival Analysis of Patients with Breast Tumor  
                                                      Univariate Analysis            Multivariate Analysis 
Variable       HR* (95% CI†)     Pvalue        HR (95% CI)      Pvalue 
Age 
   <51 years vs. >51  1.158 (0.671-1.997)  0.599 1.202 (0.692-2.086) 0.514 
Histology 
   Ductal vs. other types 1.577 (0.852-2.919) 0.147 1.379 (0.698-2.725) 0.356 
Stage 
   Early(I/II) vs. Late(III/IV) 1.662 (0.992-2.783) 0.054 2.286 (1.330-3.930) 0.003 
Grade 
   Early(I/II) vs. Late(III) 2.280 (1.266-4.105) 0.006 1.951 (1.072-3.553) 0.029 
miR-155 
   <90 vs. >90   2.619 (1.322-5.189) 0.006 2.857 (1.390 -5.874) 0.004 
*HR: Hazard Ratio 
†CI:  Confidence Ratio 
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Disscussion: 
The TNM staging of breast cancer is a standardized guideline for determining 
stage, grade, and lymph node metastasis to provide an overview of tumor behavior based 
on past observed patterns.  In general, breast cancer diagnosis with high stage, grade and 
lymph node involvement correlates with poor overall survival and indicates the necessity 
for aggressive treatment (2, 27, 41).  Interestingly, we demonstrated in this study that 
miR-155 correlates to high grade, stage, and lymph node involvement.  Furthermore, 
miR-155 expression levels are also associated with 10 year overall survival assessed 
using univariate and multivariate Cox proportional hazards model.  The same 
observations have been published in lung and pancreatic cancers (13, 33, 46).  In addition, 
we previously demonstrated that TGFβ induces miR-155 expression while promoting 
EMT by targeting RhoA, and contribute to chemo-resistance by targeting FOXO3a in 
breast cancer cell lines (20, 21).  Both findings associate miR-155 expression with 
features of aggressive tumors often characterized by invasion, metastasis and 
chemoresistance.  Collectively, these results suggest that miR-155 is involved in breast 
tumor progression. 
Over the years, as understanding in breast cancer developed, markers such as ERα, 
PR, and Her2/neu have become vital for the clinician to determine proper treatment (8, 10, 
11, 32).  For instance, adjuvant therapy where growth hormone would be blocked from 
binding their receptor would prove fruitful only if the tumor expresses ERα and PR (7, 19, 
43, 45, 49).  Similarly, Her2/neu is a cell membrane surface-bound receptor tyrosine 
kinase belonging to the epidermal growth factor receptor family.  It is involved in signal 
transduction pathways promoting cell growth and differentiation (6, 35, 37).  Its 
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presences indicates aggressive tumor, but can be treated with herceptin – an antibody 
specifically targeting Her2/neu (4, 12, 28, 39).  Computational analysis using RNA22 
(30) to determine if miR-155 may target ER, PR, or Her2/neu yielded negative results, 
and so it was not surprising that miR-155 did not correlate to the expression of these 
markers. 
In summary, our findings indicate that overexpression of miR-155 is a recurrent 
event in breast cancer and could serve as a prognostic marker, pathogenetic factor and a 
critical therapeutic target.  Future investigations are required to determine the mechanism 
by which miR-155 is up-regulated in human breast carcinogenesis. 
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CHAPTER V 
 
DISSCUSSION AND CONCLUSION: 
MicroRNAs (miRNAs) are short single stranded RNA that has been shown to 
play a significant role in oncogenesis (7, 16, 23, 39, 40, 50).  To determine the cause for 
dysregulation of microRNAs in various cancers, the biogenesis or maturation of miRs is a 
very active field of research.  Majority of miRNAs are believed to be transcribed by PolII 
machinery into a long single stranded pri-RNA (24, 25, 31).  Control of miRNA 
expression at the genomic level is similar to the regulation of protein-coding genes, with 
regulation by various transcriptional factors.  We have shown in normal mouse mammary 
gland epithelial cells (NMuMG), that TGFβ directs the transcription of miR-155 via 
Smad4 transcritional factor (Figures 5 and 6; 29).  NMuMG cells are commonly used to 
study TGFβ induced EMT (12, 43).  EMT is a mechanism that cancer cells utilize to 
initiate metastasis (33, 55, 61).  Specifically, the TGFβ ligand binds to a type II receptor 
which then recruits and phosphorylates a type I receptor.  This is followed by the 
phosphorylation of receptor bound SMAD2/3; which in turn detaches into the cytoplasm 
and combine with SMAD4 to form an active transcriptional complex that transports into 
the nucleus to regulate the expression of specific genes (41, 49, 59).  We have provided 
evidence that miR-155 is regulated in this manner by performing luciferase reporter and 
CHIP analyses (FIGURE 6; 29). 
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TGFβ is a ligand that induces EMT in NMuMG cells by modifying the expression 
of a subset of genes to induce an overall phenotype change.  Examples of such 
modification are lowered expression of typical epithelial cell markers such as E-cadherin, 
and ZO-1; and appearance of mesenchymal markers such as N-cadherin, and vimentin 
(10, 12, 43).  One example on how this occurs is described by Ozdamar et al., who  
reported that Par6 interacts with the TGFβ receptor.  In the presence of the ligand, Par6 
becomes phosphorylated and interacts with the E3 ubiquitin ligase Smurf1.  The Smurf1, 
in turn, targets the guanosine triphosphatase RhoA for degradation, thereby leading to a 
loss of tight junctions (43).  The suppression of RhoA is mandatory for dissolution of 
tight junctions during early stage of EMT.  This work provided strong evidence for the 
degradation of existing RhoA by ubiquitination in the presence of TGFβ.  If RhoA 
mRNA exists in the cytoplasm, translation would still occur to produce new RhoA that 
may replace degraded levels and prevent tight junction dissolution.  MiRNAs work by 
preventing de novo production of specific proteins via binding to the 3’UTRs of its 
targeted mRNAs.  Computational analysis using RNA22 indeed reveals multiple sites 
within the 3’UTR of RhoA where miR-155 can bind (FIGURE 9; 29) and we provided 
evidence that miR-155 expression suppresses RhoA expression (FIGURE 9) and 
contributes to tight junction dissolution, cell migration and invasion (FIGURES 7 and 8; 
29). 
FOXO3a is a well studied transcriptional factor that contains a forkhead DNA 
binding domain (2).  In the unphosphorylated form, it induces apoptosis and cell growth 
arrest by transcriptional regulation of pro-apoptotic and growth inhibitory genes in the 
nucleus.  BIM, p27, and BNIP3 are such identified downstream targets of FOXO3a (13, 
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14, 44, 53).  Upon growth factor stimulation, FOXO3a is phosphorylated by oncogenes 
such as Akt, SGK, and IKKβ (5, 6, 20, 45) and subsequently translocates from the 
nucleus into the cytoplasm where it loses its transcriptional activity.  Computational 
analysis reveals miR-155 target the 3’UTR of FOXO3a mRNA (FIGURE 12).  Baseline 
analysis for miR-155 levels in breast cancer cell lines shows high miR-155 expression in 
HS578t, MDA-MB-157 and MDA-MB-435, and correlates to lowered expression of 
FOXO3a in these cell lines (FIGURE 15 and Table 1).  On the other hand, the remaining 
tested breast cancer cell lines did not display detectable levels of miR-155, but generally 
expressed FOXO3a (FIGURE 15).  These observations suggest that FOXO3a could be 
regulated by miR-155.  We set out to prove this by performing ectopic expression and 
knockdown of miR-155 in cell lines.  In BT-474, a breast cancer cell line that normally 
expresses high FOXO3a and low miR-155, extopic expression of miR-155 reduces 
endogenous FOXO3a expression whereas knockdown of miR-155 in HS578t, a breast 
cancer cell line that doesn’t express FOXO3a but high miR-155, induces FOXO3a 
expression (FIGURE 12; 28). 
MicroRNA-155 has been shown to play an important role in physiological 
processes, especially immunology (8, 15, 34, 42, 51, 52).  In addition, early profiling 
studies have shown that miR-155 is frequently up-regulated in various types of human 
malignancy including B cell lymphoma, lung, colon, head/neck, kidney, pancreatic, and 
breast cancer (9, 16, 22, 27, 32, 56, 57).  Although we have shown that miR-155 
promotes tight junction dissolution during TGFβ induced EMT in a mouse cell line 
model, function of miR-155 in human breast cancer remains largely unknown.  Since we 
observed miR-155 targeting FOXO3a, we hypothesized that miR-155 plays a key role in 
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breast cancer chemosensitivity.  To test this, we overexpressed miR-155 in BT-474 and 
observed a decrease in apoptosis (FIGURE 11), whereas knockdown of miR-155 with 
antisense oligos (ASO) sensitizes the cells to programmed cell death (FIGURE 11; 28). 
Another breakthrough occurred in 2006 when Yanaihara, N. et al., published a 
significant correlation between miR-155 expression and overall survival in lung cancer, 
but did not offer any molecular insights to explain the phenomenon (60).  In light of this 
and two similar reports that have published similar observations in pancreatic cancer and 
squamous cell lung cancer (18, 46, 60); we set out to perform similar analysis on breast 
cancer.  We determined miR-155 expression in 154 breast cancer specimen, and 20 
normal breast tissues taken from patients who underwent surgery at H. Lee Moffitt 
Cancer center.  A near half of breast cancers express high levels of miR-155.  Statistical 
analyses suggest that miR-155 is an excellent prognostic indicator of overall 10 year 
survival (FIGURE 17 and TABLE 5). 
The AJCC TNM staging system provides a standard method for diagnosing breast 
cancer and provides the patient with a prognostic outlook; while giving the physician 
guidelines for patient care (21, 30, 47, 48).  Cancer stage, pathological grade, lymph node 
involvement are classic indicators for tumor behavior.  High grade, late stage, and 
presence of lymph node involvement are typical of aggressive tumors and often results in 
poor survivability.  We observed miR-155 also corresponds to high grade, late stage 
breast cancer and coincides with lymph node involvement greater than 10 (TABLE 4).  
However, we have shown that prognostic value of miR-155 is independent of tumor stage 
and grade. 
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ERα, PR and Her2/neu have been established as gold standard for diagnosis of 
breast cancer because they provide the basis for different therapeutic regiems (1, 3, 4, 11, 
17, 19, 26, 35-38, 54, 58, 62).  If the tumor expresses ERα or PR, adjuvant therapy such 
as tamoxifen can be used to prevent the hormones from reaching their receptor.  Similarly, 
if the tumor expresses Her2/neu, herceptin can be used to block the cell surface receptor 
from activation.  Tumors that lack all three markers are named “triple negatives” or 
“basal like,” and do not require the presence of growth signal to grow.  Triple negative 
breast cancers are often considered more aggressive since traditional chemotherapy and 
surgery are only treatment options.  However, patients still experience early recurrence 
and visceral metastasis to the brain.  Since our previous findings support the notion that 
miR-155 expression supports aggressive tumor behavior, we set out to determine if miR-
155 alters ERα, PR, or Her2/neu expression.  Computation analysis for potential miR-
155 sites in the 3’UTR of ERα, PR, or Her2/neu mRNA did not reveal ideal binding sites 
for miR-155. 
MiR-155 was identified early to be an oncogene, but not much was known on 
what role it played in cancer.  Over the years, researchers from different areas of 
specialization have supported a critical role for miR-155 in immunology (8, 15, 34, 42, 
51, 52) and leukemiagenesis (9, 16, 22, 27, 32, 56, 57).  However, the role of miR-155 in 
breast cancer remains elusive.  Our study has shown that miR-155 is induced by TGFβ 
during EMT, and targets RhoA to initiate phenotypic transition (29).  In addition, miR-
155 targets FOXO3a and induces chemoresistance in breast cancer (28).  Finally, 
statistical analysis of miR-155 expression in breast cancer also reveals an association of 
elevated miR-155 with poor overall survival, late stage and poorly differentiated tumor as 
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well as tumors with lymph node metastasis.  These findings indicate strongly that miR-
155 could serve as not only a prognostic marker and pathogenetic factor but also as a 
critical therapeutic target in breast cancer. 
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